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ABSTRACT

DEVELOPMENT OF A MODIFIED CALCIUM-BASED COMPOSITE CERAMIC
BONE GRAFT MATERIAL

By
Gavin Andrew Buckholtz
August 2015

Dissertation supervised by Professor Ellen S. Gawalt
Composites consisting of both calcium aluminum oxide and hydroxyapatite were
tested for their applicability as bone replacement scaffolds. Implanted bone scaffolds may
fail due to a variety of reasons, including mechanical and biological failure. Mechanical
failure may occur as a result of dissimilar properties between the surrounding healthy bone
and the scaffold. Biological failure can occur due to integration problems at the interface
of the scaffold and the natural bone, or as a result of implant associated infections as a
result

of

bacterial

attachment

and

biofilm

formation.

Calcium

aluminum

oxide:hydroxyapatite composites were developed that address these three modes of implant
failure through physical modification of the composition of the materials and chemical
modification of the interface of the material.

iv

The composites were evaluated for phase composition, elastic modulus, modulus
of rupture, degradability, osteoblast attachment, percent viability and proliferation.
Characterization was completed using powder x-ray diffraction (PXRD), a four point
bending test, scanning electron microscopy (SEM), scanning electron microscopy-energy
dispersive x-ray spectroscopy (SEM-EDS), diffuse reflectance infrared Fourier transform
(DRIFT) spectroscopy, fluorescence spectroscopy, direct infusion quadrupole-time of
flight mass spectrometry (Q-TOF MS), Escherichia coli N-phenylnaphthylamine (NPN)
uptake and bacterial turbidity tests, and Live/Dead® and alamarBlue® tissue culture
assays. Composites with greater than 10% HA by mass were mechanically weak and ruled
out as scaffolds. However, 1-5% HA composites were mechanically similar to non-load
bearing bone and all resulted in increased osteoblast response at extended time points. The
antimicrobial peptide Inverso-CysHHC10 was successfully linked to the 5% HA composite
using an interfacial alkene-thiol click reaction. The linked AMP retained its effectiveness
against Escherichia coli based on NPN uptake assays and bacterial turbidity tests. Most
importantly, the immobilization of the antimicrobial peptide did not affect the increased
osteoblast response observed on the unmodified 5% HA. The Inverso-CysHHC10
modified composites present a new class of composite biomaterials that are able to
simultaneously address issues with mechanical mismatching, osteoconductivity and
implant site infection.
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Chapter 1: Background
1.1 Introduction
There are more than 3 million musculoskeletal procedures performed annually in
the United States, with approximately half of those involving bone graft procedures.1 Bone
grafts are frequently used to treat skeletal injuries including fractures, tissue degenerative
diseases and bone resection, generally as a result of cancer.2-6 The autograft and the
allograft are currently the two most common methods of bone replacement, comprising
about 90% of the performed procedures.7 Only the remaining 10% of bone grafts utilize a
synthetic graft source.7 Whatever the graft source may be, the material must be able to
address the physiological stresses placed on it when it is used in an in vivo setting. The
primary stresses placed on a graft material are mechanical and biological, and due to the
nature of the autograft, it remains the most desirable source of boney tissue.8,9 However,
the extent of skeletal injury can often limit the opportunity for an autograft to be used,
based on the size and severity of the bone loss. But, with recent progress in biomaterials
research, tissue engineering and mechanical engineering, there is hope that a synthetic bone
graft material can be developed and tuned for its applicability.10-12 The ideal synthetic bone
graft material would be mechanically similar to natural bone and biologically similar to the
autograft.

1.2 Bone Scaffold Requirements
The mechanical strength and biological activity of a bone graft material are both
critical aspects in determining the applicability of a synthetic scaffold material used to fill
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a critically-sized bone defect, anything larger than 4 mm in size.13-16 Synthetic graft
materials must be mechanically similar to the natural bone that will surround them upon
implantation, resistant to corrosion and degradation under physiological condition, noncytotoxic to healthy cells, able to stimulate increased cellular attachment, viability and
proliferation and resistant to bacterial attachment and colonization.17-20

1.2.1 Mechanical Requirements
The scaffold should have similar strength to the cortical or cancellous bone that it
will be used to replace.9,21,22 This is important for a couple reasons. First, it is important
because most scaffolds are designed to act as mechanical supports for the injury site, with
the long term goal of healthy tissue eventually replacing the graft. Second, the location of
the graft will dictate the mechanical properties necessary. Natural load bearing cortical
bone, such as the femur, is much stronger than non-load bearing cancellous bone, such as
the skull or jaw, and the mechanical properties of the scaffold should be similar to those of
the natural surrounding bone.

Table 1.1: Mechanical properties of natural bone and materials used in implant procedures.

Elastic Modulus (GPa)

Modulus of Rupture (MPa)

Load Bearing
Cortical Bone23

15-22

60-75

Non-Load Bearing
Cancellous Bone23

3-11

4-9

Ti-6Al-4V Alloy
Biomaterial24

100-115

800-1000

Hydroxyapatite (Sintered)25

80-110

600-800

2

Biomaterials that are too weak provide poor mechanical support and result in
fracture or dislocation of the scaffold. But biomaterials that are stronger than the
surrounding tissue result in the stress shielding of the surrounding natural bone by the
biomaterials and can lead to bone resorption, weakening and fracture.26-28
Since bone scaffolds are designed to act as mechanical support while new, healthy
bone regenerates the material should not rapidly degrade.29 If the scaffold degrades too
rapidly, it does not give the healthy tissue an opportunity to integrate and vascularize, both
critical steps in new bone formation. Also, too rapid of degradation can lead to implant
loosening and failure. However, if the scaffold does not break down at a rate approximately
equal to the rate of new bone regeneration it can result in the buildup of boney tissue at the
scaffold-tissue interface and can also lead to implant rejection.

1.2.2 Biological Requirements
The biological requirements of a biomaterial are the most important and can often
be tuned to overcome minor mechanical differences. An ideal bone scaffold material
should be osteoconductive, osteoinductive, osteogenic and osteointegrative.21,22,30
Osteoconductivity is the ability of the scaffold to support attachment and growth of
osteoblasts, cells necessary for new bone formation.21,22,30 Osteoinductivity is the ability of
the scaffold to induce the differentiation of mesenchymal stem cells into osteoblasts.21,22,30
The ability of a material to induce this differentiation is important in the formation of new
bone cells and bone tissue. A scaffold that is osteogenic allows living cells to proliferate
on and within the material, leading to the eventual replacement of graft material with
natural tissue.21,22,30 Finally, osteointegration is the capability of the scaffold material to
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bind with the natural bone. Improper osteointegration can lead to implant dislocation and
graft failure.21,22,30
The physical properties of a scaffold material often play a role in the
osteoconductivity and osteoinductivity.19 Primarily the porosity, including size and
connectivity, of a material effect the osteoconductivity and osteoinductivity. Natural bone
can be up to 90% porous which leads to the ability to vascularize the tissue and leads to
healthy tissue formation.31-33 If a material is non-porous the cells tend to only grow on the
surface and the graft may fail.34
However, the chemical composition of the scaffold has also been shown to effect
the osteoconductivity and osteoinductivity. Where CaAlO based materials have
demonstrated the necessity of chemical functionalization for the addition of these
characteristics.35-37 Calcium phosphate materials, including β-tricalcium phosphate and
hydroxyapatite, have shown increased material osteoconductivity and osteoinductivity
through the simple addition of these phases to a variety of materials.37,38 By incorporating
these phases, it has been shown that the physical shortcomings of a material can be
overcome.

1.3 Current Bone Replacement Materials
1.3.1 Autografts and Allografts
The autograft and allograft are the only types of bone graft materials that are based
on natural human tissue. The autograft is considered the gold standard of bone graft
technology because it is the only material that supports osteoconductivity, osteoinductivity
and osteointegration.9 The autograft is a piece of bone tissue harvested from the patient’s

4

own body.39,40 This graft is the most desirable because the tissue is from the patient and
therefore the risk of immune response and disease transmission are minimized.41 However,
the procedure to acquire the autograft presents significant concerns. Obtaining the autograft
tissue requires a second surgical site and risks donor site infection, morbidity and possible
chronic pain.41,42 The final drawback to the autograft is the limitation of tissue
availability.43 The autograft has been successful in small applications, however a patient
only has a finite amount of donatable tissue. If the skeletal injury is too severe, then despite
the advantages of the autograft, an allograft is often used.
The allograft is a piece of boney tissue that is harvested from a donor, typically
shortly following death.40 Upon removal the bones are cleaned of all soft tissue and
sterilized using ethanol or gamma radiation.44,45 The sterilized bone can then be stored until
it is needed for a surgical procedure. Allografts have the benefit of a larger size availability
and they minimize the donor site complications associated with autografts.46 However,
allografts have several significant risks associated with them. Due to post resection
processing the tissue lacks osteoinductive properties and becomes mechanically
weaker.21,47 Also despite the sterilization process disease transmission from donor to
recipient has been observed.45,48,49 Finally, the biggest risk is long-term host rejection
which requires drug therapy.50,51

1.3.2 Metal Alloys and Metal Oxides
As mentioned, only about 10% of bone replacement procedures utilize a synthetic
bone scaffold material. The majority of these are metal replacements utilized when the
bone defect is critically-sized and the location of the injury is to load bearing bone.
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Frequently stainless steel, titanium and cobalt-chromium alloys are utilized in these types
of applications.52,53 Stainless steel alloys are useful as biomaterials because they are more
ductile than other alloys and the surface can be physically adjusted for surface roughness,
surface oxygen content and surface energy demonstrated that osteoblast cell adhesion,
spreading and growth rate was increased for one-day adhesion tests on CO2 laser-treated
samples.54 Also they showed that the mechanically roughened surface results in a slight
enhancement in cell proliferation.54 Titanium based alloys are regularly used as total
replacement materials because they have a high strength to weight ratio and tend to be the
most bio-inert alloy.55 Titanium alloys, including Ti-6Al-4V, have shown increased
osteoblast adhesion, differentiation and calcification when the alloy surface was rough.56
Nano-patterned titanium substrates demonstrated improved osteoblast adhesion and
morphology on linearly aligned features similar to the size and orientation of collagen and
hydroxyapatite in long bones.57 Cobalt-chromium alloys are widely used due to high
mechanical strength and hardness that limits wear over time.28 Co-Cr alloys modified with
BMP-2 showed a two-fold increase in osteoblast differentiation after two weeks and a fourfold increase in calcium deposition after three weeks.58 Both physical and chemical
modification have demonstrated their ability to increase the biocompatibility of synthetic
metal replacement devices.

1.3.3 Ceramics
Due to their chemical stability and mechanical strength, calcium aluminum oxide
cements have been evaluated for use a synthetic graft materials.59-61 CaAlO possesses a
variety of desirable characteristics for bone grafting procedures. The material is easily
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prepared using hydration, making it easy to fabricate necessary shapes and designs.35,36 In
addition to the ease of fabrication, CaAlO has low degradability and cytotoxicity, under
normal physiological conditions. CaAlO has also been shown to not lose its mechanical
strength through autoclave sterilization and is readily functionalized with cell adhesion
peptides and antibiotics using interfacial reactions.35,36
Due to the chemical similarity to natural bone, calcium phosphate ceramics have
also been investigated.16,62,63 When cast as HA, the material has been shown to be
osteoconductive and osteointegrative.38,63 The material can also be slowly resorbed through
cell mediated resorption, allowing for replacement with natural tissue.64,65 Many available
biomaterials utilize HA as part of their material, including the Vitoss Bone Graft Substitute.
HA demonstrates increased osteoconductivity and osteoinductivity, but work has also
shown that this material can be further functionalized with adsorbed antibiotics (including
vancomycin, gentamicin and ciprofloxacin) and linked antibiotics (tetracycline) to make
them even more attractive options as multifunctional synthetic bone graft materials.66-68

1.3.4 Bioactive Glasses
Bioactive glasses are hard, non-porous materials typically composed of a
combination of sodium oxide, calcium oxide, silicon dioxide and diphosphorus pentoxide
that are being investigated for bone repair.21,69 These materials are safe to implant and can
be engineered for specific purposes. First the sodium ions in the glass are replaced by
protons, then hydrolysis of the silicon dioxide leads to the precipitation of a calcium
phosphate on the material that mineralizes into HA.
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Ajita et al examined the effect of particle size on mesenchymal stem cell
proliferation of bioactive glasses.70 They have shown that the smaller the bioactive glass
nanoparticles the greater the amount of cell proliferation. Bi et al studied the effect of
bioactive glass microstructure (trabecular, fibrous and oriented) on bone regeneration in a
rat calvarial defect model.71 Twelve weeks after implantation the trabecular bioactive glass
formed new bone over 33% of the initial defect, as opposed to 23% and 15% for fibrous
and oriented. The new bone formed with trabecular bioactive glass also had a higher
average blood vessel area.

1.4 Failure of Graft Materials
1.4.1 Mechanical Failure
Failure of bone grafts is most commonly the result of mechanical issues. Corrosion
and degradation of the synthetic material in vivo often leads to decreased osteointegration
at the tissue:bone graft interface.72,73 Often the result of this is loosening of the graft in the
implant site and subsequent failure. Although metallic biomaterials tend to be made from
metals that are thought to be corrosion resistant, crevice and stress corrosion can still occur
in load bearing implants.74
Mechanical mismatching of the biomaterial to the surrounding natural tissue is
frequently a cause of failure.75,76 If the mechanical properties of the graft are different than
the tissue it is replacing then stress shielding, healthy bone resorption, implant loosening
and implant fracture can occur (Figure 1.1a).26-28 Specifically a mismatch of the elastic
modulus between natural bone (3-11 GPa for non-load bearing cancellous bone, 15-30 GPa
for load bearing cortical bone) and metallic biomaterials (~100 GPa for Ti and ~200 GPa
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for CoCr). When a biomaterial is more stiff than the surrounding natural bone, it takes
away the mechanical requirements of the natural bone.77 When the natural bone is exposed
less mechanical stress, the bone begins to resorb, weakening the tissue:graft interface and
resulting in graft failure.28
Ceramics and bioactive glasses are frequently used in non-load bearing applications
because when they are used in load bearing applications they are unable to withstand the
stresses placed on them, often ending in graft fracture.22,78 Bioactive glasses are quick to
degrade and convert to hydroxyapatite, which is an issue if the healthy tissue is not growing
back at a rate appropriate to its degradation. Ceramics, on the other hand, tend to degrade
slowly, which leads to slow integration. If the material is subjected to a stress prior to
integration, fracture and dislodging can occur.
Bone

a) Healthy bone resorption

Graft

Graft

b) Fibrous encapsulation

Bone

Graft

c) Biofilm formation

Bone

Figure 1.1: Modes of artificial graft failure including a) healthy bone resorption due to
mechanical mismatching, b) fibrous encapsulation due to non-specific protein adsorption
and c) biofilm formation due to attachment of bacteria and polysaccharide matrix
production.
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1.4.2 Biological Failure
Biomaterials can also fail as a result of biological issues. The ideal graft would be
osteoconductive, osteoinductive, osteogenic and osteointegrative, however current
biomaterials are not able to address all four of these characteristic simultaneously, and can
result in a variety of bone tissue-graft merger issues.21,22,30 Two methods of biological
failure include fibrous tissue encapsulation and infection.18,22,79-81
In the case of fibrous encapsulation, the failure is the result of an immune response
that leads to problems with implant integration and eventual implant rejection. Biomaterial
implantation results in the non-specific adhesion of proteins and cells.77,82 The presence of
blood at the surgical site leads to the production of fibrin and recruitment of white blood
cells.18 Macrophages then settle on the implant and recruit fibroblasts that create a barrier
between the tissue and the biomaterial (Figure 1.1b). Also, the adhesion of fibrinogen to
the material, which can cross-link with other proteins, can result in fibrous
encapsulation.77,83-85 If either of these two encapsulation events were to take place, the
biological response of the host would lead to significant implant loosening and eventual
failure.
Biological failure can also result from infection.82,86-88 Implant infection generally
occurs at the time of implant surgery or early on in the wound healing process.89,90 Bacteria
can adhere to the surface of the implant shortly before or immediately after surgery; since
the non-specific adhesion of proteins can form a conditioning film on the material.91 Once
the bacteria are attached they can begin to grow into bacterial colonies known as biofilms,
where the bacteria are enclosed in a polysaccharide matrix that protects them from
conventional antibiotic treatment (Figure 1.1c).82,89 Further the bacteria undergo a
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phenotype change to sessile organisms which have reduced need for nutrients. While
enclosed in the biofilm the bacteria can become more virulent, which becomes an issue
when the biofilm releases planktonic cells or biofilm clusters that can spread to other areas
of the body.92,93 Frequently the best approach to eradicate a biofilm infection is to remove
the initial implant, treat the infection, then insert a new implant.81,89,90

1.5 Current Literature Approaches to Materials Modification
1.5.1 Metal Alloys and Metal Oxides
Metals possess the mechanical strength necessary for load bearing boney
applications, but these materials tend to not be biodegradable, do not allow for cell
ingrowth, lead to increased fibrous tissue formation and can lead to stress-shielding and
healthy tissue weakening. As mentioned previously, different research strategies are being
evaluated to help increase the biocompatibility of the materials. Physical modification,
including etching and porous material fabrication, of stainless steels, titanium and cobaltchromium are being investigated to increase in vitro bone cell attachment and in vivo bone
cell in growth. By introducing pores on the metal surfaces, in vivo performance is enhanced
through increased vascularization, leading to increased nutrient supply, and increased new
bone in growth and regeneration.
Chemical modification of the surfaces of metal replacement materials has been
more widely performed as a means to improve biocompatibility of metal oxides. Stainless
steel alloys have been chemically modified with antibiotics that operate synergistically to
reduce bacterial colonization for up to 48 hours.94 The surface of the nitinol alloy has been
modified to reduce its corrosion subsequently reducing the amount of metal ions that are
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released into the body that can cause cytotoxic and genotoxic effects.95 Through the
implementation of these types of interfacial modifications the surface properties of a
variety of metals and alloys can be improved to increase their efficacy and applicability.
To overcome the issues associated with mechanical mismatching and failure
associated with stress shielding there has been work examining biodegradable metal and
alloys, including magnesium and iron.96 Using these mechanically strong, but degradable
metals, provides the temporary mechanical support with the ability to degrade in a
physiological environment while allowing for new bone regeneration.

1.5.2 Composite Materials
Composite materials aim to combine the best attributes of one material with those
of another material, to design a synthetic graft material with better function than any of the
parts individually. Composites consisting of hydroxyapatite and other bioactive ceramic
coatings on metals have shown promise by providing the bioactive properties of the coating
with the enhanced mechanical properties of the metal beneath the coating.
Chen and coworkers created a composite consisting of a titanium core with a
calcium coating. Their material was shown to induce apatite formation on the surface of
the material when submerged in simulated body fluid.97 Gu et al produced a composite
material that consisted of Ti-6Al-4V plasma-sprayed with HA. They also demonstrated the
formation of a carbonate-apatite layer after a 2 week soaking in simulated body fluid.98
Composites of HA and collagen fibers have also been investigated. Natural bone is
approximately 60% HA and 40% collagen by dry mass, so a composite of these materials
may closely mimic natural bone. Du et al and Wu et al both demonstrated that a collagen
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and HA composite produced mineralized bone in 21 days.99 Rovira and coworkers showed
that an HA-collagen-elastin composite produced mineralized bone in 15 days.99

1.5.3 Biomolecule Functionalization
Another approach to improving current biomaterials is interfacial modification with
an assortment of active biomolecules. Molecules of interest include antibiotics to limit
bacterial attachment and infection, cell adhesion peptides to promote specific cell adhesion
improving osteoconductivity, and other proteins that have been shown to induce bone
formation and vascularization. Although these modifications utilize different types of
biomolecules, they all aim to improve the surface characteristics of the biomaterials and
reduce the chance for implant failure.
The localized delivery of peptides and proteins on the biomaterial would be an
advantageous approach to increasing biocompatibility and the osteoconductive properties
of the material. Previous work has shown that modifying biomaterials with osteoblast
adhesion peptides and bone morphogenetic proteins results in better bone cell performance
and new bone formation.58,100 Several binding domains from the extracellular matrix
peptides and proteins have been revealed and incorporated into short peptides. The most
widely used is the arginine-glycine-aspartic acid (RGD) sequence.16,100 Cook et al first
showed enhanced cell spreading on RGD modified poly(lactic acid-co-lysine) polymers.101
Since that time, RGD modified materials have been used to increase fibroblast adhesion
and spreading, endothelial cell attachment and osteoblast attachment on orthopaedic
materials.36,102,103 Another example is the FDA approved InFUSE® Bone Graft that is used
in primarily in spinal surgery. This device is a composite synthetic graft that is a titanium
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cage with collagen located on the interior. The collagen is used to deliver recombinant
human bone morphogenetic protein-2 (BMP-2). This protein has been shown to induce
new bone growth by attracting osteoblast cells to the delivery site of the BMP-2.104
The delivery of active antimicrobials is also a critical part of implant success.
Research has been conducted on antimicrobial surfaces that are (1) non-fouling (surfaces
that avoid protein adsorption and cell adhesion) (2) colonized with non-pathogenic bacteria
(occupy the surface to prevent attachment of pathogenic bacteria) (3) modified with
biocidal substances (non-antibiotic molecules that have shown activity, including silver,
quaternary ammonium compounds and nitric oxide) and (4) modified with antibiotics
(vancomycin, tobramycin, ampicillin, gentamicin, etc.).105 Zhao et al and Subramani et al
have successfully immobilized vancomycin to titanium and it was proven to be bactericidal
to

Staphylococcus

aureus

(S.

aureus)

and

Staphylococcus

epidermidis

(S.

epidermidis).106,107 Palchesko et al linked vancomycin to CaAlO and demonstrated its
efficacy against S. aureus.35,108 However the utility of antibiotic coatings is dependent upon
the activity of the linked antibiotic and the growing concern over the risk of development
of antibiotic resistance in bacteria.
For these reasons, the focus has shifted for some to using antimicrobial peptides
(AMP). These antimicrobials have broad spectrum efficacy, minimize the development of
bacterial resistance and maintain effectiveness, even through sterilization.109-111 Glinel et
al, Haynie et al, Humblot et al and Bagheri et al have all linked the AMP magainin I to a
variety of materials through a variety of approaches.105 Despite different approaches the
AMP was shown to be active against bacteria including, E. coli, S. aureus, Pseudomonas
aeruginosa (P. aeruginosa) and Listeria ivanovii.105 Wilcox et al and Chen et al have linked
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melimine to contact lenses and glass cover slips and shown its activity against S. aureus
and P. aeruginosa.105 Finally, Gabriel and coworkers immobilized cathelin LL37 to
silanized titanium surfaces and demonstrated activity against E. coli.105

1.6 Summary
Although the autograft remains the optimal bone graft material due to its osteogenic
properties, the growing concerns over the source of autologous bone and the risk of
infection is driving the need to develop a better synthetic material. Currently, most
synthetic materials, including metals, alloys, ceramics, bioactive glasses and composite
materials, are not able to address all of the mechanical and biological stresses that will be
places on them in an in vivo setting. Although significant progress has been made through
the creation of composite materials and the tuning of interfacial properties through organic
functionalization with biomolecules, these synthetic materials still underachieve when
compared to the autograft. Therefore, continuing research on the development of synthetic
materials is necessary before the use of the autograft can be phased out and eliminated.

1.7 Research Approach
Artificial bone graft materials must meet several requirements. They should be
osteoconductive, osteoinductive, osteogenic and osteointegrative, all while being
mechanically similar to the surrounding natural tissue and being resistant to bacterial
attachment and colonization. Conferring all of these attributes into a single material has
been a formidable task thus far.
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This project aimed to modify the composition of the previously, physically
optimized CaAlO ceramic to enhance osteoblast response and to further develop the
antimicrobial functionalization of the composite material. A composite CaAlO material
was formed that included the osteoconductive and osteoinductive HA. As has been shown
in previous literature, the goal was to increase the osteoconductivity and osteoinductivity
of the CaAlO through this incorporation. Composites containing different percentages of
HA were cast and evaluated to find the percentages that were mechanically similar to
natural non-load bearing bone, and resulted in the greatest increase in osteoblast attachment
and proliferation.
Further, the previously designed CaAlO material required a five-step reaction
sequence to immobilize active antibiotic, vancomycin. In this project, the highly efficient,
single step alkene-thiol click reaction was used to link the antimicrobial peptide InversoCysHHC10. This linkage presents an improvement over the previous approach in multiple
regards. First, the linkage approach is shorter, more efficient and introduces the synthetic
material to less chemicals, as alkene-thiol click reactions can be performed without
initiators. Secondly, the linking of an antimicrobial peptide is advantageous over antibiotics
because antimicrobial peptides have broad spectrum efficacy, their mode of action does
not rely on bacteria growth and division and the risk of development of bacterial resistance
to antimicrobial peptides is limited.
This work evaluated the mechanical similarity of the developed composites to nonload bearing cancellous bone, examined the increased osteoconductivity of the composite
materials and determined the loading, stability and efficacy of the linked InversoCysHHC10 antimicrobial peptide.
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2 Chapter 2: Physical Characterization of Composite CaAlO:HA
2.1 Introduction
Calcium aluminum oxide materials were previously utilized as bone graft materials
and showed some promise in initial work, but they had since been discounted because of
concerns over biocompatibility.1-6 However, in vivo work has shown that the calcium
aluminum oxide materials do not illicit an inflammatory response demonstrating the
biotolerability of the CaAlO material.7-11 More recent work has further demonstrated that
through covalent chemical modification of CaAlO the biocompatibility of these materials
can be increased and biological applicability can be tuned.7,12-14 However, other work has
demonstrated that a different class of calcium ceramics, calcium phosphates, are
biocompatible and are intriguing options for synthetic bone graft materials.8,15-17
Composites of CaAlO and calcium phosphates, namely hydroxyapatite, were examined in
this project because the materials are mechanically strong and through the introduction of
the biocompatible HA, the biocompatibility of the CaAlO based material may be increased.
CaAlO casts are formed through a three-step mechanism.18,19 First the surface of
the CaAlO aggregates are hydroxylated and they begin to dissolve until the saturation limit
has been reached (dissolution).18,19 After dissolution the nuclei continue to grow in critical
size and quantity, known as the nucleation phase.18,19 Finally, the precipitation phase occurs
where the hydrates precipitate out of the solution.18,19 This process continues until all of
the dissolved CaAlO has been precipitated. During the hydration process the phases bind
together and interlock with one another, increasing the mechanical strength and forming
the cast CaAlO.
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In a previous study, a variety of different ratios of CaAlO aggregates within casts
was examined to physically optimize the material.14 The outcome was a ratio that produced
CaAlO materials that were optimized for porosity, strength and degradability.14 Despite the
optimization of the physical properties of the CaAlO material, the study revealed that the
material was not optimized for its biological performance, and required total interfacial
modification for biological activity.14
HA is formed through the hydration of calcium phosphate with phosphoric acid
(Scheme 2.1). In the first step of the formation of HA, the Ca3(PO4)2 reacts with protons in
solution to from the HA precursor brushite, CaHPO4.20 The brushite molecules then react
with water molecules and generate the solid HA phase.20 The formed solid HA molecules
are not interlocked like those in the CaAlO material, therefore the HA is mechanically
weak. To add mechanical strength to the HA, it can be sintered which fuses the powder
together by heating and compacting without reaching the melting point of the
material.21-24
Ca3(PO4)2 + 2 H+

2 CaHPO4 + Ca2+

5 CaHPO4 + H2O

Ca5(PO4)3(OH) + 2 H3PO4

Scheme 2.1: Proposed reactions for the synthesis of hydroxyapatite from calcium
phosphate tribasic.

Many prior studies have examined HA materials for their applicability as synthetic
bone graft materials.8,25-27 These studies consistently demonstrate that biomaterials
intended for boney applications often have increased biological activity when HA is
present in the material.8,27
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In casting a composite of CaAlO and HA, the mechanical integrity of the material
must be evaluated because CaAlO derives strength from through the hydration process and
HA derives strength from sintering after hydration.18-20 If the post hydration treatment
effects the mechanical integrity of the composite, then it must be determined which
procedure is more appropriate for casting materials relevant to natural bone. By using the
previously established methods for casting CaAlO and HA, to create a method to cast
composite CaAlO:HA, the physical attributes of the new CaAlO:HA material can be
physically characterized.

2.2 Materials and Methods
2.2.1 Materials
Calcium aluminum oxide (CaAlO) was supplied by Westmoreland Advanced
Materials. Calcium phosphate tribasic (Ca3(PO4)2) and phosphate buffered saline (PBS,
MgCl2 and CaCl2 free) were purchased from Sigma-Aldrich. Phosphoric acid (H3PO4) was
purchased from Fisher Scientific (Certified ACS). All materials and chemicals were used
as received unless otherwise noted.

2.2.2 Casting Calcium-Based Ceramics
2.2.2.1 Calcium Aluminum Oxide
Calcium aluminum oxide discs were prepared using a room temperature casting
(20°C) of different sized aggregates of CaAlO containing the two phases, CaAl2O4 and
CaAl4O7. The aggregate sizes utilized were -30+60, -60 and -200, in a 1:1:2 ratio, that are
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previously separated using a sifting process that sorts out the particles based on their mesh
size (Figure 2.1).13,14 The appropriate mass of each CaAlO aggregate size were thoroughly
dry mixed at room temperature to ensure even particle distribution. Distilled deionized
water (ddH2O) was then added to the aggregate powders at an amount equal to 0.3 mL of
ddH2O per gram of CaAlO. The paste was allowed to thicken at room temperature for 10
minutes. Afterwards, the CaAlO was poured into either: 1) a 6x2 mm (diameter x height)
cylindrical disc mold or a 2) 17.75x2.5x1.67 cm (length x width x height) rectangular prism
mold, where it was allowed to set for four hours. The CaAlO casts were rehydrated in their
molds with ddH2O, and allowed to set overnight. The next day the casts were hydrated in
their molds using ddH2O, then allowed to set for the night. The following day casts were
removed from their molds and immersed into ddH2O for 24 hours to ensure hydration of
the material.

-30+60

-60

+

-200

+

ddH2O
CaAlO aggregate
packing and binding
within cast material

Figure 2.1: Casting 100% CaAlO in a 2:1:1 ratio of three different aggregate sizes.
Through hydration the aggregates can be cast into a variety of shapes.

2.2.2.2 Hydroxyapatite
Hydroxyapatite discs were also prepared using a room temperature cast
approach.28,29 Fine particles of calcium phosphate tribasic were first obtained by grinding
the Ca3(PO4)2 powder in a mortar and pestle for 10 minutes. Once the powder was ground,
it was hydrated using a dilute phosphoric acid (H3PO4, 25 mM) solution at an amount equal
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to 1.1 mL of H3PO4 per gram of Ca3(PO4)2 (Figure 2.2). Again the paste was allowed to
thicken at room temperature for 10 minutes. After thickening the Ca3(PO4)2 was poured in
the same molds as above, where it was allowed to set for four hours. After four hours the
material was rehydrated in the molds using H3PO4, then allowed to set overnight. The
following day the casts were rehydrated with H3PO4 in the molds and set for another night.
The next day the casts were removed from their molds, rehydrated with H3PO4 for 24 hours
and then were sintered for four hours at 1000°C using a programmable Lindberg/Blue
Moldatherm Box Furnace (Model: BF51866A). The furnace was programmed to heat up
from room temperature to 1000°C over a span of two hours, then remain at 1000°C for four
hours, followed by a two hour cool down from 1000°C to room temperature.

Sintered HA

Cast HA

Ca3(PO4)2

H3PO4

1000°C

Figure 2.2: Casting 100% HA using ground Ca3(PO4)2 with 25 mM H3PO4. After casting
the materials are sintered for strength.

2.2.2.3 Calcium Aluminum Oxide:Hydroxyapatite Composites
Calcium aluminum oxide:hydroxyapatite (HA) composite discs (1-5, 10, 15, 20 and
25%, by mass) were cast using a room temperature method that combined both the CaAlO
and the HA methods. First the three different aggregate sizes of CaAlO (-30+60, -60 and 200) were dry mixed in a 1:1:2 ratio. Upon thorough mixing, ground Ca3(PO4)2 was added
to the mixed CaAlO powder at a mass appropriate for the desired composite composition
(1-5, 10, 15, 20 or 25% HA, by mass). The powders were again thoroughly dry mixed to
distribute the particles and then were hydrated with 0.3 mL of ddH2O per gram CaAlO and
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1.1 mL H3PO4 per gram Ca3(PO4)2 in the composite. For example, 15 grams of a composite
that is 95% CaAlO and 5% HA (known as 5% HA), required 7.125 grams of -200 mesh
CaAlO, 3.563 grams each of the -60 and -30+60 mesh CaAlO, and 0.75 grams of
Ca3(PO4)2. Upon mixing, 4.28 mL of ddH2O and 0.83 mL of H3PO4 was used to hydrate
the powder. The paste was allowed to thicken for 10 minutes. Afterwards the paste was
poured into the same molds mentioned above, where it was allowed to set for four hours,
then was rehydrated using H3PO4 and allowed to set overnight. Composites were hydrated
again the next day with H3PO4 and permitted to set overnight. The following day
composites were removed from their casts and were rehydrated in ddH2O for 24 hours.
Once hydrated, half of the composite discs/beams were allowed to dry at room
temperature (simulating exclusive CaAlO casting) and half were subjected to a four hour
sintering at 1000°C (simulating exclusive HA casting). The two post hydration processes
were examined because CaAlO derives much of its mechanical strength through using
ddH2O to create chemical bonds between the aggregate powders during hydration, whereas
mechanical integrity of HA is the result of sintering, the high temperature compaction and
fusion of powders into solids.

2.2.3 Powder X-ray Diffraction
Phases present in the cast composites were determined using powder x-ray
diffraction (PXRD).14,30,31 Six discs of each material (100% CaAlO, 100% HA and 1-5, 10,
15, 20 and 25% HA) were ground with a mortar and pestle for 20 minutes. Samples were
then loaded onto an X’Pert PANalytical Pro and scanned from 5-70° 2Θ with a time per
step of 720.090 seconds and a scan speed of 0.002947° per second. Collected diffraction
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patterns were analyzed using X’Pert High Score Plus to match peaks in the collected
sample patterns to reference database patterns. Peak overlap between the sample and
reference patterns indicated a matched phase.

2.2.4 Mechanical Evaluation
Eight total beams of each composite (0-5, 10, 15, 20 and 25% HA) were cast. Four
composite beams were sintered at 1000°C for four hours and the other four were dried at
room temperature. All composite beams were evaluated independently by mounting in an
MTS 858 Bionix test machine in a fully articulated four point bending fixture (Figure 2.3).
The middle supports were placed at 25% and 75% of the distance from the left, and a light,
hollow, square brass structural beam of 6x6 mm with 0.4 mm walls was attached to the
midpoint of the lower side of the beam, perpendicular to the axis of symmetry. Each side
of the beam was in contact with a linear variable differential transformer. A tare load of 70
N was applied to the beam and the deflection at the midpoint was recorded. Beams were
then loaded at a speed of 0.5mm/s until failure, and the load and deflection were recorded.
The average elastic modulus and the average modulus of rupture of each composite was
then calculated and compared to the value for non-load bearing cancellous bone.

Figure 2.3: CaAlO:HA composite beam loaded in the four point bending apparatus, prior
to load application.
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The elastic modulus and modulus of rupture were calculated according to equations
1 and 2, respectively. Where “l” is the distance between the two outer most loading points,
“Fmax” is the maximum applied load, “b” is the specimen width, “h” is the specimen
thickness, “ΔF” is the load range between a maximum 350 N load and the 70 N tare load
and “f” is the difference in the midpoint beam deflections at 350 N load and the 70 N tare
load.
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏. Elastic Modulus =

11 ∙ ∆F ∙ l3
64 ∙ f ∙ b ∙ h3

𝐄𝐪𝐮𝐭𝐚𝐢𝐨𝐧 𝟐. Modulus of Rupture =

3 ∙ Fmax ∙ l
4 ∙ b ∙ h2

2.2.5 Scanning Electron Microscopy
Morphological characteristics of the cast composite materials (0-5% HA) were
examined using scanning electron microscopy (SEM). Characteristics including composite
topography and interfacial porosity were examined. Micrographs were collected between
250-1400x magnification using a 2.00-7.00 kV accelerating voltage, dependent upon the
surface feature and material being examined. Substrates were analyzed on a Hitachi S3400N-II SEM under full vacuum.

2.2.6 Scanning Electron Microscopy-Energy Dispersive X-Ray
Spectroscopy
Interfacial composition and interfacial phase distribution of the cast composite
materials (0-5% HA) were examined using scanning electron microscopy-energy
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dispersive x-ray spectroscopy (SEM-EDS) and elemental mapping. EDS spectra were
collected on areas of the substrates that were large and flat, allowing for data collection
over an area instead of a single point. Spectra were collected for two minutes from 0-20
eV. Maps of all elements detected using EDS were also obtained. Elemental maps were
collected on the same region of the substrate as the EDS spectra was collected. Maps for
all elements were simultaneously collected for the duration of four minutes. All substrates
were analyzed and spectra/maps collected on a Hitachi S-3400N-II SEM under vacuum
using a Bruker XFlash with ESPIRIT software, under a magnification of 1400x and
accelerating voltage of 15.0 kV.

2.2.7 Degradability Study
The long term stability of the composite material in an aqueous environment was
evaluated through immersion in phosphate buffered saline (PBS) for three months at 37°C
and 5% CO2. Ten discs each of 0-5% HA were cast and weighed for their initial mass,
recorded as week 0 (n=10). Discs were then added to individual wells of a 48 well plate,
immersed in 1 mL of PBS and placed into an incubator at 37°C and 5% CO2. Well plates
were removed from the incubator weekly, and the discs were transferred from the well
plate into test tubes and then were heated at 120°C for 4.5 hours to ensure the removal of
the liquid. Each disc was individually massed at the weekly time point. The discs were then
placed into individual wells of a new 48 well plates, immersed in 1 mL of fresh PBS and
they were returned to the incubator for another week. This process was carried out weekly
for the duration of three months and the average change in mass between weeks was
determined for each composite.
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2.2.8 Statistics
A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used
to determine the averages and examine statistical differences between the elastic moduli
and moduli of rupture of the cast composites (0-5, 10, 15, 20 and 25% HA) and between
the sintered and RT-formed composites. Additionally, the average weekly change in mass
of all of the composites was compared. Both were evaluated at the p<0.05 level of
significance and all data is reported as mean ± standard error.

2.3 Results
2.3.1 Powder X-Ray Diffraction
To determine the phases present in the composite materials, PXRD was utilized.
The phases of the CaAlO starting aggregates are CaAl4O7 and CaAl2O4. Phases present in
the room temperature cast 100% CaAlO include CaAl4O7, CaAl2O4, and a new hydrated
calcium aluminum phase, Ca3Al2(OH)12.14 In the composite materials (1-5, 10, 15, 20 and
25% HA) Ca3(PO4)2, was added in as the source of HA. PXRD analysis of the RT-formed
composites revealed the same three phases of CaAlO, as well as Ca5(PO4)3(OH), which is
HA, and trace amounts of the HA precursor, CaHPO4·2H2O (Figure 2.4).
The presence of the same phases in both the RT-formed composites and the
exclusively cast CaAlO and Ca3(PO4)2 demonstrates that the phases are not mixing and no
cross reactions are taking place when the composites are cast. Thus the osteogenic benefits
of the HA phase may be preserved through the RT casting.
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Figure 2.4: A) PXRD pattern for the 5% HA composite and phases contained within the
composite. Including the calcium aluminum oxide based phases B) CaAl4O7, C) CaAl2O4
and D) Ca3Al2(OH)12 and the calcium phosphate based phases E) Ca5(PO4)3(OH) and
F) CaHPO4·2H2O.

2.3.2 Mechanical Evaluation
Different post hydration procedures were examined because CaAlO derives its
mechanical strength from hydration, whereas the mechanical integrity of HA is the result
of sintering. Composites ranging from 0-5, 10, 15, 20 and 25% HA were cast into two
groups (sintered: heated at 1000°C for 4 hours and RT-formed: dried at room temperature)
and evaluated for their elastic modulus and modulus of rupture.32,33 When examining bone
for these properties, the value depends largely on the bone type, location and purpose. 32,34
Cortical bone is the dense, rigid bone tissue that is found largely in load bearing locations,
whereas cancellous bone is the porous, more flexible bone tissue found primarily in nonload bearing locations.32 Both the elastic modulus and modulus of rupture of cortical bone
have been shown to be higher than those of cancellous bone.32 However, mechanically
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matching a composite CaAlO to either of these types of bone would be useful for guiding
the materials applicability.

2.3.2.1 Elastic Modulus
The elastic modulus of a material is a measure of the resistance to non-permanent
deformation when an external force is applied. Beams composed of 100% CaAlO cast at
room temperature were found to have an average elastic modulus of 14.5 ± 0.9 GPa. As
HA was incorporated into the mixture it was found that the elastic modulus of the
CaAlO:HA composites tended to decrease as the mass percent of HA increased.
Specifically, the 1%, 3% and 4% HA composites were statistically equivalent to control
100% CaAlO, the 2% HA composite was statistically higher (16.2 ± 0.5 GPa) than control
and the 5, 10, 15, 20 and 25% HA composites had a statistically lower elastic moduli than
control (Figure 2.5).
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Figure 2.5: Average elastic modulus of the composites of sintered and RT-formed 0-5, 10,
15, 20 and 25% HA composites, shown as mean ± standard error, p<0.05. RT-formed
composites are statistically higher for all percentages evaluated.
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Table 2.1: Elastic modulus of the sintered and RT-formed CaAlO:HA composites.
Material
0% HA
1% HA
2% HA
3% HA
4% HA
5% HA
10% HA
15% HA
20% HA
25% HA

Sintered/RT-formed
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed

Elastic Modulus (GPa)
14.5 ± 0.9
1.8 ± 0.3
15.9 ± 0.9
3.1 ± 0.3
16.2 ± 0.5
2.5 ± 0.4
13.8 ± 1.4
2.7 ± 0.2
13.9 ± 1.1
2.6 ± 0.3
9.9 ± 1.1
1.4 ± 0.1
5.2 ± 0.4
0.9 ± 0.1
3.7 ± 0.6
0.2 ± 0.02
3.2 ± 0.7
0.7 ± 0.1
2.6 ± 0.5

In spite of the statistical differences amongst the composites, the elastic moduli for
the 5, 10, 15, 20 and 25% HA RT-formed composites were all within the reported range
for non-load bearing, structural cancellous bone, between 3-11 GPa (Table 2.1).32,35 All of
the composites, 1-5, 10, 15, 20 and 25% HA, had elastic moduli lower than that reported
for cortical bone.
The RT-formed beams were also compared to their sintered counterparts. The
results demonstrate that sintering the composites at 1000°C for 4 hours significantly
decreases the elastic modulus of the material for all of the composites examined. The 5%
HA composite had the smallest average difference (70% decrease) between sintered and
RT-formed materials and the maximum difference found was for the 1% HA composite
(90% decrease).
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2.3.2.2 Modulus of Rupture
The modulus of rupture of a material is a measure of the ultimate force necessary
to cause failure. Composites that were 100% CaAlO cast at room temperature were found
to have an average modulus of rupture of 8.8 ± 0.9 MPa. As HA was incorporated into the
mixture it was found that at low percentages the modulus of rupture was not significantly
affected and at high percentages the modulus of rupture decreased. Specifically, the RTformed 1% and 3-5% HA composites were statistically equal to control 100% CaAlO, the
2% HA composites were statistically higher (10.8 ± 0.6 MPa) than control CaAlO and the
10, 15, 20 and 25% HA composites were lower than control (Figure 2.6).
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Figure 2.6: Average modulus of rupture of the composites of sintered and RT-formed 05, 10, 15, 20 and 25% HA composites, shown as mean ± standard error, p<0.05. RT-formed
composites are statistically higher for 1-5% HA and statistically equal at greater
percentages of HA.

Despite statistical differences among the composites, the moduli of rupture for the
RT-formed 1, and 3-5% HA composites were all within the reported range for non-load
bearing, structural cancellous bone, between 4-9 MPa (Table 2.2).32,35 The modulus of
rupture of all of the composites were significantly lower than cortical bone.

40

Table 2.2: Modulus of rupture of the sintered and RT-formed CaAlO:HA composites.
Material
0% HA
1% HA
2% HA
3% HA
4% HA
5% HA
10% HA
15% HA
20% HA
25% HA

Sintered/RT-formed
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed
Sintered
RT-formed

Moduli of Rupture (MPa)
8.8 ± 0.9
2.9 ± 0.6
10.1 ± 0.6
5.0 ± 0.4
10.8 ± 0.6
4.1 ± 0.3
9.7 ± 0.4
4.5 ± 0.2
9.1 ± 0.4
3.9 ± 0.1
6.4 ± 0.7
3.0 ± 0.3
2.8 ± 0.2
1.6 ± 0.3
2.0 ± 0.1
0.4 ± 0.03
1.6 ± 0.1
1.1 ± 0.2
1.4 ± 0.1

RT-formed beams were again compared to their sintered counterparts,
revealing that sintering the 1-5% HA composites caused a significant decrease in the
modulus of rupture, but at higher percentages of HA sintering did not significantly affect
the modulus of rupture. The smallest percent difference in average strength between
sintered and RT-formed materials was found for the higher percentage composite 10%,
15% and 25% HA composite (10-20% decrease) and the largest difference was for the 1%
HA composite (70% decrease).

2.3.3 Scanning Electron Microscopy
After using the mechanical evaluation to focus the study on mechanically-relevant
composites, the 0-5% HA composites were qualitatively evaluated using SEM to determine
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material morphology. It was found that the 100% CaAlO material adopted a topography
that was rough and non-uniform, containing surface structures that were needle-like, platelike and cubic (Figure 2.7 A-C). As small mass percentages of HA were added into the
CaAlO, the topography of the composites became more uniform and the distinct surface
structures observed in 100% CaAlO were no longer present. The interface of the
composites appear smoother, like that of cast 100% HA (Figure 2.7 D-E).
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Figure 2.7: Morphological SEM images of surface structures observed on CaAlO, 5% HA
and HA. A) Needle-like formation of CaAlO. B) Plate-like formation of CaAlO. C) Cubelike formation of CaAlO. D) Increased surface uniformity observed on 5% HA, similar to
interfacial characteristics of HA. E) Interfacial structure of 100% HA.

2.3.4 Energy Dispersive X-Ray Spectroscopy
The interfacial composition of the 0-5% HA composites was evaluated using SEMEDS and elemental mapping to determine the elemental and phase composition. Interfacial
analysis confirmed the presence of the elements calcium, aluminum and oxygen in all 05% HA composites examined, as a result of the CaAl4O7, CaAl2O4 and Ca3Al2(OH)12 in
cast CaAlO (determined using PXRD). As Ca3(PO4)2 was incorporated into the material, it
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cast as the phase HA, Ca5(PO4)3(OH) (determined using PXRD), and was present at the
composite interface, determined by the presence of the EDS peak corresponding to
phosphorus at 2.0 eV and elemental mapping of phosphorus. Additionally, the intensity of
the EDS peak corresponding to phosphorus increased as the composite increased from 1%
to 5% HA, indicating that as the mass percentage of HA in the composite increased, the
amount of HA present at the interface also increased. A greater interfacial amount of HA
is significant because it can lead to increased exposure and interaction between osteoblasts
and the osteogenic phase of the composite.
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Figure 2.8: EDS spectra for 0, 1, 3 and 5% HA exhibit the presence of calcium, aluminum,
and oxygen from the CaAlO phases. The 1, 3 and 5% HA composites contain phosphorus
due to the HA and brushite phases. Elemental mapping shows the distribution of the HA
phase at the composite interface based on the location of the phosphorus atoms and the
aluminum atoms show that the majority of the interface is CaAlO.
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2.3.5 Degradability Study
The long term stability of the 1-5% HA composites and control CaAlO was
evaluated by immersion in PBS for 3 months. Substrates were placed into individual wells
of a 48 well plate, immersed in 1 mL of fresh PBS and put into an incubator at 37°C and
5% CO2. Substrates were removed from the incubator weekly and PBS was driven off then
substrates were weighed.
Overall, the 1-5% HA composites exhibited a similar trend in their average weekto-week change in mass when compared to one another. However, between Week 0 and 1
the composites (1-5% HA) experienced a statistically significant drop in mass compared
to the control CaAlO. For example, the average decrease in mass of control during Week
1 was 0.23 ± 0.34 milligrams and for 5% HA it was 1.94 ± 0.35 milligrams. This decrease
in mass can be attributed to the dissolution of solid CaAlO and/or Ca3(PO4)2 that remains
in the composites after the casting process, because these phases are soluble in water.
However, the observed decrease in mass during the first week was not statistically different
among the 1-5% HA composites (Figure 2.9).
Between Weeks 1 and 2 the mass of control CaAlO and 1%, 2%, and 5% HA all
increased by statistically the same mass, and 3% HA and 4% HA increased by a
significantly greater amount than the others. Specifically, in Week 2 the control increased
by 2.22 ± 0.30 milligrams and the 5% HA by 2.20 ± 0.28 milligrams, whereas the 3% HA
increased by 3.01 ± 0.18 milligrams. Despite the differences in the mass changes in the
early weeks of the assay, the mass change of all samples (0-5% HA) converged to zero
grams when the degradability assay was extended through 3 months, indicating that the
material was not degrading and remained stable in the PBS (Figure 2.9).
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Figure 2.9: Average change in mass from week to week for 0-5% HA composites over a
3 month time span.

2.4 Discussion
The 100% CaAlO had previously been physically characterized for interfacial pore
size and volume, phase presence, degradability and fibroblast attachment.14 It was
determined that the 2:1:1 ratio of -200, -30+60 and -60 CaAlO aggregate sizes resulted in
the material that was physically the most applicable, with pores of 100 μm diameter, no
free Al3+ ions, long term stability in PBS and increased fibroblast (scar tissue cells)
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adhesion at short time points.14 In spite of the fact that the material was physically
optimized and increased fibroblast adhesion, it required chemical optimization to allow for
bone cell attachment.12,14 This chemical modification was important because it introduced
a five-step reaction sequence that culminated in the linkage of KRSR, an osteoblast
adhesion peptide, and vancomycin, an antibiotic active against gram-positive strains of
bacteria.12,13 Through the introduction of the osteogenic HA into the materials, the goal
was to maintain the material’s mechanical strength while increasing osteoblast response,
and decreasing the extent of chemical modification necessary to develop a multifunctional
bone graft material.
Ca3(PO4)2 was added to the CaAlO powder as the source of HA for the composite
material. When the composite materials are cast, PXRD demonstrated that the Ca3(PO4)2
does cast into HA. However, to analyze the composites using PXRD the discs had to be
ground into a fine powder following the casting, therefore PXRD demonstrated the
presence of the HA phase in the disc, but the location of the HA in the discs is also very
important. Also, when exclusive HA materials are used, the material must be sintered in
order to provide mechanical strength and decrease solubility, therefore these characteristics
needed to be reexamined for the composites.
The strength of the CaAlO phase is due to the hydrated phases that form during the
casting process and interlock the different aggregates within the material. Despite the
hydration steps in the HA casting phase, its strength comes from sintering and fusing the
powders. Since the two materials being cast into one composite differ in their mechanism
for obtaining strength, both processes were examined. Sintering the composites had a
significant effect on the elastic modulus and modulus of rupture for the composites with

46

less than 5% HA. All of these composites had significantly reduced values as a result of
sintering. This is due to the removal of the hydrating waters of the CaAlO phases. By
driving these waters out of the composite at 1000°C, the CaAlO phases weaken and
therefore weaken the composite as a whole. Conversely, when the 1-5% HA composites
were simply hydrated and dried at room temperature, the elastic modulus and modulus of
rupture was not affected. This is because the materials are between 95-99% CaAlO and
CaAlO strength is the results of interlocked phases from hydration. Further when the elastic
modulus of the composites was compared to non-load bearing cancellous bone, it was
found that the 5, 10, 15, 20 and 25% HA composites were within the reported range of 311 GPa.32,35 The 1-4% HA composites were very close to this value, no more than 4 GPa
higher (observed with 2% HA). The modulus of rupture of non-load bearing cancellous
bone is reported between 4-9 MPa.32,35 The 1 and 3-5% HA composites had moduli of
rupture within this range and the 2% HA was 1 MPa higher. As the composites became
>10% HA they were significantly lower than this range. Structural cancellous bone is 100%
stronger than composites with >10% HA. Mechanical evaluation demonstrated that RTformed composites with between 1-5% HA were the most mechanically relevant materials
to natural, structural cancellous bone.
The results of the mechanical evaluation indicated that the RT-formed 1-5% HA
composites were mechanically similar to non-load bearing bone. The distribution of the
HA phase within the cast composites is important to their success. The distribution is
important for a few reasons, first, cellular interactions will take place at the scaffold-tissue
interface, so when cast some HA must be present at the interface, and secondly because
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sintering reduces the degradability of HA in vitro. But, since the composites were not being
sintered, the presence of HA at the interface may lead to increased material degradability.
The presence and distribution of HA at the interface of all 1-5% HA composites
was demonstrated using SEM-EDS. The EDS spectra collected on all composites revealed
the presence of the elements calcium, aluminum, oxygen and phosphorus. Based on the
data collected with PXRD, it can be established that the presence of phosphorus is the result
of HA or the HA precursor and not starting Ca3(PO4)2 or any mixed calcium aluminum
oxide-calcium phosphate phases. It was also found that as the amount of HA in the
composite increases from 1% to 5% the interfacial amount of phosphorus increased. This
indicates that by increasing the amount of Ca3(PO4)2 in the cast powder, the amount of HA
at the interface will increase accordingly. This is important because it shows that the HA
phase is distributed and abundant at the material-tissue interface. Furthermore, the
degradability assay was carried out on the composite materials at physiological temperature
and verified that the in vitro stability of the materials was not significantly affected.

2.5 Conclusions
Composite materials consisting of calcium aluminum oxide and hydroxyapatite
were successfully cast at room temperature to contain 1-5, 10, 15, 20 and 25% HA by mass.
By casting the composites of CaAlO with small mass percentages of HA, the mechanical
strength of the CaAlO material was not significantly affected. The 1-5% HA composites
were up to 190% stronger than other composites and were better mechanical matches for
non-load bearing cancellous bone. Importantly, the incorporated HA (1-5%) was present
and distributed at the composite interface where cellular interactions could occur, and the
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composites were stable in vitro in PBS at 37°C and 5% CO2 for 3 months. Based on these
results the 1-5% HA composites were investigated for their ability to increase osteoblast
response in vitro.
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3 Chapter 3: Increased Osteoblast Response on 1-5% HA
Composites
3.1 Introduction
When synthetic bone graft materials are used they can lead to the formation of
fibrous tissue around the implant which may inhibit new bone growth and integration at
the graft-tissue interface.1-4 This encapsulation is caused by non-specific cell and protein
adhesion due to the normal wound healing response.3 If fibrous encapsulation does occur
it can lead to bone resorption at the graft-tissue interface which can lead to implant
loosening and graft failure. One approach to increasing cell adhesion has been to link cell
adhesion peptides to the surfaces of the graft materials.5-10 Initially studies demonstrated
that the peptide RGD increased the attachment of a variety of cells (osteoblast, fibroblasts,
mesenchymal stem cells) to an assortment of materials (calcium ceramics, titanium,
polymers).5,11-14 The biggest issue with RGD is that it is a non-cell specific adhesion
peptide and as a result it may lead to increased fibrous tissue at the graft-tissue
interface.12,15-18 To address this, research has shifted to cell specific adhesion peptides.6,19
The osteoblast specific adhesion peptide KRSR has been shown to bind an increased
number of osteoblasts compared to unmodified surfaces (titanium, calcium ceramics).6,2022

KRSR has also been shown to preferentially bind osteoblasts over fibroblasts when

immobilized to 100% CaAlO.6 These cell adhesion peptide based approaches do result in
increased osteoblast response on modified materials, but materials based approaches have
shown that calcium phosphate containing materials can increase osteoblast response.23-25
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Miljkovic and coworkers compared three calcium based ceramics in an in vivo rat
calvarial critical-sized defect model.23 They compared CaAlO, RGD-modified CaAlO and
a calcium phosphate, β-tricalcium phosphate, and demonstrated that CaAlO and RGDCaAlO did not have osteoconductive or osteoinductive properties on their own and both
cause a mild immune reaction at the site of implantation.23 Conversely, the β-tricalcium
phosphate did not illicit an immune response and showed signs of implant integration into
the host tissue at 4 weeks.23 This work showed that unmodified calcium phosphate
ceramics were a more viable option for increased in vivo bone regeneration over CaAlO
and modified CaAlO.
Ball and coworkers used pulsed laser ablation as a method for deposition of HA
onto titanium surfaces.24 Human osteoblasts were seeded onto the material surfaces and
examined for a variety of cellular responses. The HA coated surfaces supported greater cell
attachment, were more supportive of proliferation and growth and caused increased
differentiation based on alkaline phosphatase presence.24 The osteoblasts on HA coated
titanium also had a more organized actin cytoskeleton and had more contacts with the
surface, determined by vinculin staining.24 They showed that by coating the mechanically
strong titanium with a thin HA layer, the in vitro osteoblast performance was greatly
improved.
Finally, Pino-Minguez and coworkers created composites of polymethylmethacrylate alone and mixed with HA in different concentrations.25 They examined
composite PMMA:HA with 5%, 10%, 15% and 20% HA.25 PMMA has been studied due
to its strength, however osteoblasts have shown limited activity when they are in contact
with it, and it is common to observe fibroblastic cells at the PMMA-bone interface.25
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PMMA:HA composites were investigated in an attempt to enhance the biocompatibility of
the PMMA. They demonstrated the maximum amount of osteoblast growth and
differentiation between 15% and 20% and that the transition between encapsulation and
bone growth was at 15%.25 They revealed that by creating a composite of the mechanically
strong PMMA and the osteoinductive HA, the in vitro bone cell response was significantly
improved when the composites contained 15% and 20% HA.
In this study, the composite CaAlO:HA materials that were mechanically similar to
non-load bearing bone (1-5% HA composites) were evaluated for their ability to increase
in vitro osteoblast response. Based on the literature, it has been shown that the presence of
calcium phosphates, either as β-tricalcium phosphate or HA, in biomaterials causes an
increase in the biocompatibility of the coated or composite materials. Here, the effect of
the addition of HA to the CaAlO material was examined through osteoblast attachment,
viability and proliferation of cells seeded on the sterilized composites.

3.2 Materials and Methods
3.2.1 Materials
Calcium aluminum oxide (CaAlO) was supplied by Westmoreland Advanced
Materials. Calcium phosphate tribasic (Ca3(PO4)2) and phosphate buffered saline (PBS,
MgCl2 and CaCl2 free) were purchased from Sigma-Aldrich. Phosphoric acid was
purchased from Fisher Scientific (Certified ACS). Normal human osteoblasts (NHOsts),
osteoblast subculturing reagents (HEPES buffered saline, Trypsin/EDTA, Trypsin
neutralizing solution) and osteoblast basal medium (OBM) were purchased from LONZA.
The Live/Dead® Viability/Cytotoxicity assay kit and alamarBlue® reagent were
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purchased from Life Technologies. All materials and chemicals were used as received
unless otherwise noted.

3.2.2 Casting Calcium-Based Ceramics
3.2.2.1 Calcium Aluminum Oxide
Calcium aluminum oxide discs were prepared using the same method described in
Chapter 2. The three different aggregate sizes of CaAlO utilized were -30+60, -60 and 200, in a 1:1:2 ratio, that are previously separated using a sifting process that sorts out the
particles based on their mesh size. The appropriate mass of each CaAlO aggregate size
were thoroughly dry mixed at room temperature to ensure even particle distribution.
Distilled deionized water (ddH2O) was then added to the aggregate powders at an amount
equal to 0.3 mL of ddH2O per gram of CaAlO. The paste was allowed to thicken at room
temperature for 10 minutes. Afterwards, the CaAlO was poured into either a 6x2 mm
(diameter x height) cylindrical disc mold where it was allowed to set for four hours. The
CaAlO casts were rehydrated in their molds with ddH2O, and allowed to set overnight. The
next day the casts were hydrated in their molds using ddH2O, then allowed to set for the
night. The following day casts were removed from their molds and immersed into ddH2O
for 24 hours to ensure hydration of the material. CaAlO discs were sterilized before cellular
studies by autoclaving at 121°C and 18 psi of steam for 60 minutes with fast exhaust.
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3.2.2.2 Calcium Aluminum Oxide:Hydroxyapatite Composites
Calcium aluminum oxide:hydroxyapatite (HA) composite discs (1-5% HA) were
cast using the same method described in Chapter 2. First the three different aggregate sizes
of CaAlO (-30+60, -60 and -200) were dry mixed in a 1:1:2 ratio. Upon thorough mixing,
ground Ca3(PO4)2 was added to the mixed CaAlO powder at a mass appropriate for the
final composition to be 5% HA. The powders were thoroughly dry mixed together and
hydrated with 0.3 mL of ddH2O per gram CaAlO and 1.1 mL H3PO4 per gram Ca3(PO4)2
in the composite. The paste thickened for 10 minutes, then was poured into the 6x2 mm
cylindrical molds. The paste set for four hours, then was rehydrated using H3PO4 and
allowed to set overnight. Composites were hydrated again the next day with H3PO4 and
permitted to set overnight. The following day composites were removed from the mold and
rehydrated in H3PO4 for 24 hours. The 5% HA discs were sterilized before cellular and
bacterial studies by autoclaving at 121°C and 18 psi of steam for 60 minutes with fast
exhaust.

3.2.3 Osteoblast Cell Culture
Normal human osteoblasts (NHOsts) isolated from a 2 year old male (LONZA)
were thawed from a -200°C liquid N2 dewar and plated into T-25 cm2 tissue culture flasks
with at least 125,000 cells per flask in 5 mL of osteoblast basal medium (OBM). Tissue
culture flasks were then placed into an incubator at 37°C and 5% CO2 for 24 hours, so live
osteoblasts could adhere to the interior. In the flasks, osteoblast attachment and division
was monitored daily until attached cells achieved approximately 80% confluence. OBM
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was changed daily after initial seeding during the days leading up to 80% confluence in the
flask.
Once cells reached 80% confluence they were subcultured out of the flasks and a
cell trial was begun. Osteoblasts were subcultured according to the protocol provided by
LONZA and counted using the hemocytometer with Trypan Blue. Nine autoclaved
composite discs per time point (0-5% HA) were placed into individual wells of 48 well
plates labeled as Days 1, 4 and 7. Osteoblasts were then diluted to 10,000 cells per mL in
OBM, and 1 mL of this osteoblast solution was added to each well containing a disc. OBM
was changed daily in the individual wells leading up to each time point.

3.2.4 Osteoblast Attachment to 1-5% HA
NHOsts isolated from a 2 year old male were purchased from LONZA, cultured
until 80% confluent and diluted to a concentration of 10,000 cells per mL of OBM. Three
sample sets of three discs per time point (Days 1, 4 and 7, nine total discs) were autoclaved
and seeded with 10,000 osteoblasts. After 1, 4 and 7 days the number of attached live and
dead cells was determined using the Live/Dead® Viability/Cytotoxicity assay kit from Life
Technologies (Figure 3.1).6,26-28
Using this assay kit, live cells will fluoresce green and dead cells will fluoresce red.
Five spots on each sample with an area of 0.6 mm 2 were imaged under 10x magnification
using the Axioskop2 with AxioVision software and fluorescence filters. The number of
live cells was then counted on all 45 images for each composite percentage for each day
(1-5% HA), then normalized to the control 100% CaAlO.
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Calcein AM
Ethidium Homodimer
Esterase

Calcein

DNA Binding

Nucleus

Dead Cell

Live Cell

Figure 3.1: Fluorescent based Live/Dead® Viability/Cytotoxicity assay where calcein AM
enters a live cell and is digested by an esterase to result in the green fluorescent cells. The
ethidium homodimer enters a dead cell and binds to the DNA in the nucleus resulting in
the red fluorescent cells.

3.2.5 Osteoblast Viability on 1-5% HA
NHOsts isolated from a 2 year old male were cultured and treated the same as
described in Section 3.2.4. Cells were again assayed using the Live/Dead®
Viability/Cytotoxicity assay kit and Axioskop2. In this assay, however, both the living
(green) and dead (red) cells were counted on the 45 images of each composite for each day,
getting a total number of cells. The percent viability was determined by dividing the
number of live cells in each image by the total number of cells in each image.

3.2.6 Osteoblast Proliferation on 1-5% HA
NHOsts isolated from a 2 year old male were cultured to 80% confluence and
diluted to 10,000 cell per mL of OBM. Then 1 mL of the osteoblast solution was added to
nine wells containing autoclaved discs (0-5% HA). Cell proliferation was evaluated using
the alamarBlue® assay from Life Technologies (Figure 3.2).29-32 In this assay the
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alamarBlue reagent, resazurin, is reduced to resorufin through metabolic processes that
take place during cell division and the extent of reduction is correlated to the amount of
cellular growth. The alamarBlue® reagent was added to the OBM in the wells in a 1:40
dilution 24 hours prior to UV-VIS analysis on Days 1, 4 and 7. The absorbance of the
alamarBlue reagent at 570 nm, corresponding to resorufin, was collected for all nine
samples at each day using an Agilent Technologies Cary 100 UV-VIS spectrometer. The
absorbance values of all of the composites on all days were normalized to the control 100%
CaAlO.

NADP
NAD

NADPH
NADH

Dividing Cells

Dead Cells

Figure 3.2: AlamarBlue® assay for osteoblast proliferation. If there are living, dividing
cells in the wells, the alamarBlue® reagent is reduced and a color change can be observed
and quantified by UV-VIS. If there are dead cells in the wells, the alamarBlue® reagent is
not reduced.

3.2.7 Statistics
A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used
to determine the averages and statistical differences between the NHOst attachment,
viability and proliferation at the p<0.05 level of significance and all data is reported as
mean ± standard error.
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3.3 Results
3.3.1 Osteoblast Attachment to 1-5% HA
To determine if the incorporation of the osteogenic HA into the CaAlO:HA material
increased osteoblast attachment over control 100% CaAlO, NHOsts (LONZA) were
cultured and seeded onto autoclaved discs (0-5% HA). Nine sterilized discs per time point
were placed into a 48 well plate and loaded with 10,000 NHOsts. After 1, 4 and 7 days the
cells were imaged using the Live/Dead® Viability/Cytotoxicity assay kit (Figure 3.3). Five
images per disc were collected and the number of live cells was normalized to CaAlO.
1% HA

2% HA

3% HA

4% HA

5% HA

Day 7

Day 4

Day 1

0% HA

Figure 3.3: Representative Live/Dead® fluorescent images of osteoblasts attached to
control 100% CaAlO and 1-5% HA composites on Days 1, 4 and 7.

On Day 1 the normalized average number of live osteoblast cells per view was:
control CaAlO: 100.0 ± 11.9; 1% HA: 96.4 ± 5.8; 2% HA: 101.5 ± 5.8; 3% HA: 96.0 ±
5.9; 4% HA: 104.1 ± 4.8; 5% HA: 125.4 ± 6.0 (Figure 3.4). Only the 5% HA had a
statistically greater number of attached live cells than control CaAlO.
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Figure 3.4: Day 1 normalized average number of live osteoblasts attached to control and
1-5% HA composites. * = statistically higher than control and all other composites. Data
represented as mean ± standard error, p<0.05.

On Day 4 the normalized average number of live osteoblast cells per view was:
control CaAlO: 100.0 ± 12.0; 1% HA: 141.9 ± 11.2; 2% HA: 146.2 ± 11.5; 3% HA: 143.2
± 7.8; 4% HA: 145.8 ± 6.6; 5% HA: 185.7 ± 10.2 (Figure 3.5). Composites consisting of
1-4% HA had a statistically greater number of live cells than control, but were equivalent
to one another. However, the 5% HA composite exhibited statistically increased live
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osteoblast attachment when compared to both the control and the 1-4% HA composites.
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Figure 3.5: Day 4 normalized average number of live osteoblasts attached to control and
1-5% HA composites. # = statistically higher than control and * = statistically higher than
control and all other composites. Data represented as mean ± standard error, p<0.05.
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On Day 7 the normalized average number of live osteoblast cells per view was:
control CaAlO: 100.0 ± 11.8; 1% HA: 121.2 ± 9.3; 2% HA: 124.7 ± 6.8; 3% HA: 126.4 ±
8.9; 4% HA: 117.4 ± 5.4; 5% HA: 142.4 ± 5.6 (Figure 3.6). Composites with 1-4% HA
had a statistically greater number of live cells when compared to control CaAlO, but similar
to Day 4 they were all statistically equal to one another. The 5% HA had a statistically the

Normalized Average Live Cells/View

greater number of live cells than the control CaAlO and 1-4% HA composites.
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Figure 3.6: Day 7 normalized average number of live osteoblasts attached to control and
1-5% HA composites. # = statistically higher than control and * = statistically higher than
control and all other composites. Data represented as mean ± standard error, p<0.05.

3.3.2 Osteoblast Viability on 1-5% HA
To examine the effect of HA on osteoblast viability, NHOsts (LONZA) were
cultured and seeded onto autoclaved discs (0-5% HA). Nine sterilized discs per time point
were placed into a 48 well plate and loaded with 10,000 NHOsts. After 1, 4 and 7 days the
cells were imaged using the Live/Dead® Viability/Cytotoxicity assay kit. Five images per
disc were collected. The number of live cells was divided by the total number of cells to
determine the percent viability of the attached NHOsts.
On Day 1 the percent cell viability was: control CaAlO: 60.7 ± 4.7; 1% HA: 73.2
± 2.3; 2% HA: 67.6 ± 2.5; 3% HA: 67.8 ± 2.5; 4% HA: 81.4 ± 1.6; 5% HA: 83.0 ± 1.7
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(Figure 3.7). The 1%, 4% and 5% HA composites had statistically higher percent cell
viability than control CaAlO. The 2% and 3% HA composites did not have an increased
percent cell viability on Day 1 over control.
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Figure 3.7: Day 1 percent viability of attached cells on control and 1-5% HA composites.
# = statistically higher than control. Data represented as mean ± standard error, p<0.05.
The percent cell viability on Day 4 was: control CaAlO: 57.5 ± 4.2; 1% HA: 74.2
± 2.3; 2% HA: 77.0 ± 2.5; 3% HA: 81.6 ± 1.6; 4% HA: 79.5 ± 1.6; 5% HA: 81.7 ± 2.1
(Figure 3.8). All of the 1-5% HA composites had statistically increased percent cell
viability when compared to control CaAlO.
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Figure 3.8: Day 4 percent viability of attached cells on control and 1-5% HA composites.
# = statistically higher than control. Data represented as mean ± standard error, p<0.05.
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On Day 7 the percent cell viability was: control CaAlO: 69.6 ± 4.2; 1% HA: 81.2
± 2.8; 2% HA: 88.1 ± 1.5; 3% HA: 84.6 ± 1.9; 4% HA: 87.6 ± 1.3; 5% HA: 84.9 ± 1.6
(Figure 3.9). Again, the percent viability was significantly higher on all of the composites
compared to control CaAlO.
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Figure 3.9: Day 7 percent viability of attached cells on control and 1-5% HA composites.
# = statistically higher than control. Data represented as mean ± standard error, p<0.05.

3.3.3 Osteoblast Proliferation on 1-5% HA
To determine if the presence of HA had an effect on osteoblast proliferation,
NHOsts were cultured and seeded onto sterilized discs (0-5% HA). Nine discs at each time
point were placed into 48 well plates and loaded with 10,000 NHOsts. Before evaluating
osteoblast proliferation, the alamarBlue® reagent was diluted in the OBM. After 1, 4 and
7 days the OBM was examined using UV-VIS spectroscopy (Figure 3.10). The absorbance
of the OBM from each well was collected and normalized to control CaAlO.

65

C

1%

2%

3%

4%

5%

Figure 3.10: Representative OBM solutions for Day 7 of the alamarBlue® assay for
control and 1-5% HA.

On Day 1 the normalized average absorbance was: control CaAlO: 1.00 ± 0.02, 1%
HA: 1.00 ± 0.03, 2% HA: 1.06 ± 0.02, 3% HA: 1.12 ± 0.03, 4% HA: 1.24 ± 0.02, and 5%
HA: 1.22 ± 0.03 (Figure 3.11). Based on the absorbance, the 4% and 5% HA composites
exhibited a statistically greater amount of cell proliferation compared to all other samples,

Normalized Absorbance @ 570 nm

while the 2% and 3% HA were higher than 1% HA and control.
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Figure 3.11: Day 1 normalized absorbance at 570 nm of control and 1-5% HA composites.
# = statistically higher than control. Data represented as mean ± standard error, p<0.05.

All of the composites had significantly increased cell proliferation compared to
control by Day 4, however the 5% HA supported the greatest amount of proliferation. The
normalized average absorbance on Day 4 was: control CaAlO: 1.00 ± 0.01, 1% HA: 1.09
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± 0.02, 2% HA: 1.12 ± 0.01, 3% HA: 1.12 ± 0.01, 4% HA: 1.14 ± 0.02, and 5% HA: 1.20

Normalized Absorbance @ 570 nm

± 0.03 (Figure 3.12).
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Figure 3.12: Day 4 normalized absorbance at 570 nm of control and 1-5% HA composites.
# = statistically higher than control and * = statistically higher than control and all other
composites. Data represented as mean ± standard error, p<0.05.

At Day 7 the normalized average absorbance was: control CaAlO: 1.00 ± 0.02, 1%
HA: 1.22 ± 0.02, 2% HA: 1.23 ± 0.02, 3% HA: 1.34 ± 0.04, 4% HA: 1.41 ± 0.06 and 5%
HA: 1.51 ± 0.03 (Figure 3.13). Similar to Day 4, all of the composites exhibited
significantly greater cell proliferation than the control CaAlO. The cells on the 5% HA
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composite again supported the highest amount of proliferation.
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Figure 3.13: Day 7 normalized absorbance at 570 nm of control and 1-5% HA composites.
# = statistically higher than control and * = statistically higher than control and all other
composites. Data represented as mean ± standard error, p<0.05.
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3.4 Discussion
The osteogenic HA phase was shown to be present at the composite surface without
adversely affecting the mechanical integrity of the material. In vitro osteoblast tests
examined if increasing the amount of HA at the interface played a significant role in bone
cell performance when cultured on the composites. The composites were evaluated for
their ability to increase osteoblast attachment and percent viability, and their ability to
support increased cell proliferation. If the presence of the osteoinductive HA at the
interface plays a significant role in the osteoblast response, the materials with increasing
amounts of HA should result in the best composite material.
On the extended time points of the osteoblast assays (Days 4 and 7), the 5% HA
composites had the greatest number of attached live cells and supported the greatest amount
of cell proliferation, compared to control CaAlO and the 1-4% HA composites. Whereas
the percent viability of attached cells was increased on all composites over control CaAlO.
The greatest increase in cell attachment and proliferation on the 5% HA is the result of the
exposure of the cells to the osteoconductive and osteoinductive HA at the tissue-material
interface. This result is in agreement with the work of Pino-Minguez and coworkers, where
they demonstrated the maximum amount of osteoblast growth, proliferation and
differentiation at higher percentage composites of PMMA and HA.25 In their work, they
observed the maximum cellular response between 15% and 20% HA, and found that at
greater than 20% HA the PMMA:HA composites lost their mechanical integrity.25
Based on the physical and biological evaluation of the 1-5% HA composites, the
5% HA composite is the most applicable for a cancellous bone scaffold material. The 5%
HA had an elastic modulus and modulus of rupture similar to non-load bearing cancellous
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bone and consistently resulted in increased osteoblast attachment, viability and
proliferation on all days examined. This composite was the only one to enhance cellular
response on each day examined. These results are in agreement with previous work in the
literature that has demonstrated that composite materials containing HA increase bone
regeneration more than the non-HA containing materials.23-25 Further, this CaAlO:HA
composite material is mechanically stronger than HA alone and is easier to synthesize.
More importantly, in the past increased in vitro osteoblast performance and in vivo
bone regeneration using CaAlO based materials required interfacial modification with
biomolecules.6,23,28,33 Various organic molecules, cell adhesion peptides and osteogenic
proteins have been immobilized to the CaAlO in order to increase bone cell
response.6,23,28,33 A result of the necessity to chemically modify the material is multiple
synthetic reaction steps. These synthetic steps may introduce harmful chemicals to the
materials, result in the deactivation of the linked biomolecule or require two separate
reaction systems to simultaneously immobilize multiple functionalities on the
material.6,23,28,33 In using this materials-based approach, where composites that contain HA
at the interface, bone cells are able to perform significantly better than control samples and
interfacial modification of the material is not required.25

3.5 Conclusions
In vitro osteoblast attachment, percent viability and proliferation were all
successfully enhanced on the RT formed 1-5% HA composites. Through the incorporation
of osteogenic HA into the composite, and the HA phase presence at the material interface
(confirmed using SEM-EDS) all of the indicators of cellular response were improved
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compared to 100% CaAlO at the extended time points, Days 4 and 7. Further, the 5% HA
composite was the only material that resulted in increased cell attachment, percent viability
and proliferation at the short time point, Day 1. Not only was the 5% HA the only material
to mechanically match the elastic modulus and modulus of rupture of non-load bearing
cancellous bone, but it was also the only material that significantly increased osteoblast
attachment, percent viability and proliferation on all days examined. Based on these results
the 5% HA is the appropriate CaAlO:HA composite to use when increased cellular
response is desired on mechanically relevant materials.
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Chapter 4: Creating a Multifunctional Composite Ceramic by
Antimicrobial Peptide Immobilization to the 5% HA
4.1 Introduction
The formation of bacterial biofilms on the surfaces of medical implants is a serious
clinical problem that may result in infection, implant failure, revision surgery and
death.1-7 Between 5-14% of initial orthopedic joint replacement surgeries result in implant
failure.8-10 Bacterial biofilms are chronic infections that occur on implant surfaces and are
one of the most serious causes of implant failure.11-13 Infection typically occurs at the time
of surgery, where bacteria on the skin can enter the wound and colonize the implant
surface.3,12-17 Therefore, limiting bacterial attachment to the implant is important in limiting
implant failure.
Upon attachment the planktonic bacteria undergo a phenotype change into sessile
organisms which produce a protective polysaccharide matrix and have a reduced need for
nutrients.14,16,18 The extracellular matrix protects the bacteria from their surrounding
environment, including any antibiotics that may be employed for treatment.19-21 Further,
the matrix-enclosed bacteria can spread to other regions of the body, through shedding of
biofilm clusters or the release of planktonic cells, making it difficult to determine the
infection location and can lead to severe infections and even death (Figure 4.1).2,10,13,14,17,22
Conventional treatments are frequently insufficient because they require high doses of
antibiotics and contribute to antibiotic resistance in the biofilm.5,23-26 Frequently the only
way to treat a biofilm infection is to remove the implant and install a new one, however
this does not eliminate the risk of re-infection of the new material.12,13,15,17,27
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Irreversible attachment

Replication and Matrix
production

Shedding and Release

Figure 4.1: Steps in biofilm formation on the implant surface include irreversible bacterial
attachment of planktonic bacteria, bacterial replication and polysaccharide matrix
production and shedding of biofilm clusters and release of planktonic cells.

Since the bacteria within the biofilm are sessile and tend to not grow and divide,
current research aims to prevent biofilm formation by limiting the initial bacterial
attachment.28-30 Some approaches include the use of physical adsorption of antibiotics into
the biomaterials, that way when placed into the physiological environment, the antibiotics
leach from the material and treat the bacteria that are in the biomaterials vicinity.31-33 In
using this approach, groups have seen that the majority of the antibiotics tend to release
from the material very rapidly and do not remain localized to surgical site.34,35 In other
studies, antibiotics have been covalently immobilized to the materials in an attempt to keep
the treatment localized to the surgical site.36,37 Many studies have shown that this approach
keeps the antibiotic localized to the material and that the antibiotics maintain some form of
activity against bacterial challenge.36,37 However, other work has shown that the
immobilization of antimicrobials reduces their effectiveness against bacteria.38 Also,
reaction schemes must be developed that use functional groups within the antibiotic that
are not part of the mechanism of action, and because the antibiotics have specific modes of
action, the orientation of the immobilized molecules must be considered.39,40
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As an approach to limit the risk of development of antibiotic resistant bacterial
strains, antimicrobial peptides (AMP) are being investigated.41-43 AMPs are short peptides
that are part of the innate immune response to pathogens.44 Many AMPs have broad
spectrum efficacy against both gram positive and gram negative bacteria.44,45 Most
importantly AMPs have low minimum inhibitory concentrations and a fast-acting
mechanism.44 AMPs form membrane pores that compromise cell viability, this is important
in biofilm applications because the AMP mechanism of action does not rely on bacteria
growth and division like it does in many common antibiotics (Figure 4.2).44,46-48

Cell Exterior
Cell Interior

Antimicrobial peptide with
hydrophobic (blue) and hydrophilic
(red) amino acid residues.

Figure 4.2: A proposed mechanism of AMP action is membrane pore formation where
hydrophobic amino acids allow for intercalation of the peptide into the phospholipid
membrane of bacteria, and hydrophilic amino acids form the interior of the pore.

Inverso-CysHHC10 is a synthetic AMP (H-CKRWWKWIRW-NH2, all D-amino
acids, Scheme 4.1) shown to be highly effective against common biofilm forming bacteria
either when in solution or when covalently incorporated into a flexible polyethylene glycol
hydrogel.49,50 HHC10 has an LC99.9 (lethal concentration to 99.9% of inocula) of 8 μM
against the common biofilm forming bacteria, S. aureus, S. epidermidis and E. coli.49,50
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HHC10 is also proteolytically stable because it is composed of the nonproteinogenic Damino acids. It has been shown that greater than 90% of HHC10 remains intact after
soaking in pooled human serum for 25 hours.49 The HHC10 was also shown to be noncytotoxic to sheep erythrocytes, as only 1% of the initially seeded cells did not survive after
incubation with HHC10.49 Lastly, HHC10 has been amended to include the cysteine
residue at the N-terminus of the peptide. Cleophas et al demonstrated that the addition of
this cysteine residue does not affect the activity of the AMP in solution, and the cysteine
residue facilitates the ease of immobilization of HHC10 to materials.50

Scheme 4.1: Inverso-CysHHC10 containing the hydrophobic tryptophan and isoleucine
amino acids and hydrophilic arginine and lysine amino acids. The sacrificial cysteine is
appended to the N-terminus.

The goal in this work was to covalently attach HHC10 to the mechanically
optimized and biologically preferred 5% HA composite to add antimicrobial properties to
the synthetic graft material. Each of the two steps in the attachment were verified using
DRIFT and the activity of the linked HHC10 against E. coli was evaluated using the NPN
uptake assay and a bacterial turbidity test. Lastly, in an ideal multifunctional system the
function of one modification should not affect the function of another. Therefore osteoblast
performance on the HHC10 modified 5% HA discs was also re-examined.
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4.2 Materials and Methods
4.2.1 Materials
Calcium aluminum oxide (CaAlO) was supplied by CAberTech, Inc. (Monessen,
PA).

Calcium

phosphate

tribasic

and

2-hydroxy-4’-(2-hydroxyethoxy)-2-

methylpropiophenone (Irgacure 2959, 98%) were purchased from Sigma-Aldrich.
Phosphoric acid (Certified ACS), tetrahydrofuran (THF, Optima, 99.9%) and 4-(2hydroxyethyl)-piperazine ethanesulfonic acid (HEPES, 99%) were obtained from Thermo
Fisher Scientific. The THF was distilled over sodium and benzophenone prior to use. 16heptadecenoic acid (16-ene, 97%) was purchased from Apollo Scientific and N,Ndimethylformamide (DMF, 99.8%) from Acros Organics. The antimicrobial peptide,
Inverso-CysHHC10, (HHC10, >90.0%, H-CKRWWKWIRW-NH2) was obtained from
GenScript USA, Inc. as a lyophilized powder and reconstituted in doubly distilled water
(ddH2O). N-phenylnaphthylamine (NPN, 98%) was purchased from Ultra Scientific and
Luria Bertani medium (LB media) was from MP Biomedicals. The LB media capsules
were dissolved in 50 mL of ddH2O and autoclaved before use. Escherichia coli (ATCC®
25922) was obtained from ATCC. Normal human osteoblasts, osteoblast subculturing
reagents (HEPES buffered saline, Trypsin/EDTA, Trypsin neutralizing solution) and
osteoblast basal medium (OBM) were purchased from LONZA (Walkersville, MD). The
Live/Dead® Viability/Cytotoxicity Assay Kit and alamarBlue® reagent were purchased
from Life Technologies. All materials and chemicals were used as received unless
otherwise noted.
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4.2.2 Casting Composite 5% HA
Calcium aluminum oxide:hydroxyapatite (HA) composite discs (5% HA only)
were cast using the same method previously described in Chapter 2 and 3. First the three
different aggregate sizes of CaAlO (-30+60, -60 and -200) were dry mixed in a 1:1:2 ratio.
Upon thorough mixing, ground Ca3(PO4)2 was added to the mixed CaAlO powder at a mass
appropriate for the final composition to be 5% HA. The powders were thoroughly dry
mixed together and hydrated with 0.3 mL of ddH2O per gram CaAlO and 1.1 mL H3PO4
per gram Ca3(PO4)2 in the composite. The paste thickened for 10 minutes, then was poured
into the 6x2 mm cylindrical molds. The paste set for four hours, then was rehydrated using
H3PO4 and allowed to set overnight. Composites were hydrated again the next day with
H3PO4 and permitted to set overnight. The following day composites were removed from
the mold and rehydrated in H3PO4 for 24 hours. The 5% HA discs were sterilized before
cellular and bacterial studies by autoclaving at 121°C and 18 psi of steam for 60 minutes
with fast exhaust.

4.2.3 Covalent Antimicrobial Peptide Immobilization
The antimicrobial peptide Inverso-CysHHC10 was attached to the 5% HA surface
using a two-step solution deposition method. First, warm (60°C) 5% HA discs were
immersed in a 1 mM 16-heptadecenoic acid (16-ene) solution (dry THF) for one hour at
room temperature. Excess solvent was removed by placing the discs on a 0.1 torr vacuum
line for 24 hours. The 16-ene modified discs were then placed into a solution of 1 mg/mL
HHC10 and 0.5 mg/mL Irgacure 2959 in 10:1 ddH2O:DMF.51 The HHC10 solution
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containing the 16-ene modified discs was then reacted under 365 nm UV light for 3 hours
with N2 purge. Again, excess solvent was removed on a 0.1 torr vacuum line for 24 hours
(Scheme 4.2). Both 16-ene and HHC10 modified 5% HA discs were rinsed in solvent prior
to analysis. Discs were sterilized by autoclaving at 121°C and 18 psi of steam for 60
minutes with fast exhaust prior to cellular and bacterial assays.

Scheme 4.2: Reaction sequence utilized for the covalent immobilization of HHC10 to
composite 5% HA. First the material is modified with 16-heptadecenoic acid, then an
alkene-thiol click reaction is used to link HHC10 at the interface.

4.2.4 Diffuse

Reflectance

Infrared

Fourier

Transform

Spectroscopy
A Thermo Nicolet Nexus 470 FT-IR spectrophotometer equipped with a diffuse
reflectance attachment was used to obtain spectra of the modified composites following
each step of HHC10 immobilization. Each step of the covalent modification served as the
background spectra for the subsequent step in the sequence. Spectra were collected for
1024 spectral scans (4000-400 cm-1) with a resolution of 4 cm-1.
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4.2.5 Quantification of Antimicrobial Peptide Immobilization
on 5% HA
Using a Horiba Scientific Fluoromax-4 Spectrofluorometer, the amount of HHC10
immobilized to the 5% HA was measured. Quantification using fluorimetry was possible
because HHC10 contains four tryptophan residues, with the fluorescent indole side chain,
and an excitation wavelength of 285 nm.52,53 A five point calibration curve with stock
concentrations of 0.025, 0.050, 0.075, 0.100 and 0.200 mg of HHC10 per mL of 10:1
ddH2O:DMF was prepared (n=5 per concentration). The stock solutions were prepared
using the same reaction conditions that were used to immobilize HHC10 to the 5% HA,
described in Section 4.2.3. Fluorescence emission spectra were collected from 250-450 nm
with the maximum emission used for quantification observed at 342 nm. Ten HHC10
modified 5% HA discs were prepared using a 1 mg/mL HHC10 solution with 0.5 mg/mL
Irgacure 2959 in 10:1 ddH2O:DMF and 16-heptadecenoic acid modified 5% HA discs
(prepared as described in Section 4.2.3). After the immobilization reaction was complete,
the 5% HA discs were removed from the solution and the solution fluorescence was
collected. The concentration of HHC10 remaining in the solution was quantified using the
calibration curve. The resulting average change in concentration from before HHC10
immobilization to after was correlated to how much HHC10 had been immobilized to the
5% HA discs (n=10).
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4.2.6 Quantification of Antimicrobial Peptide Released from
Modified 5% HA
To quantify the amount of HHC10 that remained immobilized to the 5% HA discs,
direct infusion mass spectrometry was used. Six HHC10 modified 5% HA discs were
soaked in 2 mL of ddH2O for 1, 3.5 and 24 hours. At each time point the discs were
removed from the water and moved into a fresh 2 mL of ddH2O. The ddH2O from each
time point was filtered using a 0.2 μm syringe filter and 0.1% formic acid (total volume)
was added to assist in the HHC10 ionization process. A five point calibration curve based
on the instrument signal at [HHC10+3H]3+ was prepared with concentrations of 9.0x10-9,
5.0x10-8, 1.5x10-7, 3.0x10-7 and 5.0x10-7 M, all with 0.1% formic acid (n=5 per
concentration). The six samples at each time point were then analyzed with an Agilent
Technologies

6530

Accurate-Mass

Quadrupole-Time

of

Flight

Liquid

Chromatography/Mass Spectrometry (Q-TOF MS) with High Performance Liquid
Chromatography-Chip Cube Mass Spectrometry Interface using an FIA-Chip (II). Samples
were analyzed in positive ionization mode using the following instrument settings: Gas
temperature=325°C, Drying gas=4.0 L/min, Capillary voltage=1900 V, Fragmentor
voltage=175 V, Skimmer voltage=65 V and Octapole1 voltage=750 V. Sample and stock
solutions were subtracted from a ddH2O and 0.1% formic acid background and the
concentration of HHC10 in solution was quantified using the calibration curve (n=6).
Based on the volume of the samples, the mass of HHC10 in solution was determined and
the percent of HHC10 remaining linked after soaking was calculated based on the amount
immobilized determined in Section 4.2.5.
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4.2.7 Escherichia coli Culture
Escherichia coli (E. coli) purchased for American Type Culture Collection
(ATCC® 25922) were thawed from a -80°C freezer and placed into a T-25 cm2 cell culture
flask. One full inoculation loop of E. coli was added to 15 mL of the prepared LB media
and placed onto the shaker incubator. Flasks of E. coli were left in the shaker incubator
long enough to grow to an optical density at 600 nm (OD600

nm)

of 0.5 for the N-

phenylnaphthylamine uptake assay and 0.1 for the bacterial turbidity test.

4.2.8 Escherichia coli NPN Uptake Factor on Modified 5% HA
A fluorescence assay based on the uptake of a nonpolar probe, Nphenylnaphthylamine (NPN), was used to monitor the changes in permeability of the
membrane of E. coli when mixed with HHC10 modified 5% HA discs.54,55 If the bacteria
membrane is compromised, NPN enters the phospholipid environment and increased
fluorescence can be observed (Figure 4.3).

λex = 355 nm
λem = 405 nm

Figure 4.3: NPN uptake assay for determination of E. coli membrane permeability. If the
HHC10 effectively lyses the membrane the NPN can enter the hydrophobic environment
and increased fluorescence of NPN can be observed. If the membrane remains intact the
NPN cannot enter and fluorescence is not observed.
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A planktonic E. coli culture was grown to an initial optical density at 600 nm
(OD600 nm) of 0.5 in Luria-Bertani media (LB media). The cells were centrifuged for 10
minutes at 1000 g, then resuspended in one-half of their initial volume of 5 mM HEPES at
pH 7.2. A 5 mM NPN solution, in acetone, was prepared, and diluted to 40 μM with HEPES
immediately before use.
For a standard fluorescence measurement using the PerkinElmer VICTOR3
Multilabel Plate Reader, the microtitre plate wells (ten/sample) were supplemented with
200 μL total of HEPES, E. coli, NPN and 5% HA discs, dependent on the sample. Wells
that contained E. coli and NPN always had 100 μL and 50 μL respectively, with HEPES
accounting for the remaining volume. Sample wells were (i) HEPES + unmodified 5% HA
disc; (ii) HEPES + NPN + unmodified 5% HA disc; (iii) HEPES + E. coli + unmodified
5% HA disc; (iv) HEPES + E. coli + NPN + unmodified 5% HA disc; (v) HEPES + E. coli
+ HHC10 modified 5% HA disc; (vi) HEPES + E. coli + NPN + HHC10 modified 5% HA
disc. The E. coli solution was always added last, immediately preceding fluorescent
measurement, and the values were collected within three minutes of E. coli addition. The
NPN uptake factors were then calculated as a ratio of background-corrected (subtracted by
the value in the absence of NPN) fluorescence values of the E. coli suspension and of the
HEPES buffer.54,55 The NPN uptake factor of the treated E. coli was normalized to the NPN
uptake factor of untreated E. coli (n=1000).
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4.2.9 Escherichia coli Bacterial Turbidity Tests with Modified
5% HA
An analysis based on bacterial optical density was used to monitor the effect of
immobilized HHC10 on the growth of the gram-negative E. coli (Figure 4.4).36,56 A
planktonic culture of E. coli was diluted to an initial OD600 nm of 0.1 in LB media. Two
milliliters of the planktonic E. coli solution were placed into 15 mL centrifuge tubes. There
were four tubes of each sample: (i) E. coli + unmodified 5% HA disc and (ii) E. coli +
HHC10 modified 5% HA disc. After preparing the samples, the centrifuge tubes were
placed in a shaker incubator at 37°C for 2.5 hours. After the incubation period, the OD600
nm

of each sample was recorded using an Agilent Technologies Cary 100 UV-VIS

spectrometer. Three replicates of each sample were collected and the average OD600 nm of
HHC10 modified 5% HA (ii) treated E. coli was normalized to the untreated E. coli (i).

Planktonic
E. coli
culture

Unmodified
E. coli
solution

HHC10
modified
E. coli
solution

37°C,
2.5 hours
>OD600 nm>

Figure 4.4: Bacterial turbidity test for the evaluation of E. coli growth in culture. If HHC10
reduces bacterial growth, the concentration of E. coli in solution will be smaller and the
OD 600 nm will be lower than untreated bacteria.
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4.2.10 Inverso-CysHHC10 Antimicrobial Activity in Solution
and on Modified 5% HA
Using the NPN uptake factor and bacterial turbidity tests previously described in
Section 4.2.8 and 4.2.9, the efficacy of the immobilized HHC10 against E. coli was
compared to the free, in solution HHC10 to determine the concentration dosage that the
linked AMP was equally as effective as.
In the NPN assay eight samples were prepared and treated using the same
approach.54,55 The first six samples were the same as those in Section 4.2.8 and now
included (vii) HEPES + E. coli + 10 μM HHC10 solution (50 μL) + unmodified disc and
(viii) E. coli + 10 μM HHC10 solution (50 μL) + NPN + unmodified 5% HA. The NPN
uptake factors were calculated using the same method and the treated E. coli (both 10 μM
solution and linked to 5% HA) were normalized to the untreated E. coli.
In the bacterial turbidity test, the bacteria was prepared using the same method and
the two samples in Section 4.2.9 were the same and one additional sample was added (iii)
E. coli + 10 μM HHC10 + unmodified 5% HA disc.36,56 The average OD600 nm of the treated
E. coli (both solution and linked) was normalized to the untreated E. coli.

4.2.11 Osteoblast Cell Culture
NHOsts isolated from a 2 year old male were thawed from a -200°C liquid N2 dewar
and plated into T-25 cm2 tissue culture flasks with at least 125,000 cells per flask in 5 mL
of OBM. Tissue culture flasks were placed into an incubator at 37°C and 5% CO2 for 24
hours so live osteoblasts could adhere to the interior. In the flasks, NHOst attachment and
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division was monitored daily until approximately 80% confluence. OBM was changed
daily after initial seeding during the days leading up to 80% confluence in the flask.
Once cells reached 80% confluence they were subcultured out of the flasks and a
cell trial was begun. NHOsts were subcultured according to the protocol provided by
LONZA and counted using the hemocytometer with Trypan Blue. Nine autoclaved HHC10
modified 5% HA discs per time point were placed into individual wells of 48 well plates
labeled as Days 1, 4 and 7. NHOsts were then diluted to 10,000 cells per mL in OBM, and
1 mL of this NHOst solution was added to each well containing a disc. OBM was changed
daily in the individual wells leading up to each time point.

4.2.12 Osteoblast Attachment to Modified 5% HA
NHOsts isolated from a 2 year old male were purchased from LONZA, cultured
until 80% confluent and diluted to a concentration of 10,000 cells per mL of OBM. Three
sample sets of three discs per time point (Days 1, 4 and 7, nine total discs) were autoclaved
and seeded with 10,000 NHOsts. After 1, 4 and 7 days the number of attached live and
dead cells was determined using the Live/Dead® Viability/Cytotoxicity assay kit from Life
Technologies.56-59 The number of live cells was counted on all 45 images for control
unmodified 5% HA and HHC10 modified 5% HA. The amount of attached lived cells on
HHC10 modified 5% HA was normalized to the control unmodified 5% HA.

4.2.13 Osteoblast Viability on Modified 5% HA
NHOsts isolated from a 2 year old male were cultured and treated the same as
described in Section 4.2.11. Cells were again assayed using the Live/Dead®
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Viability/Cytotoxicity assay kit and both the living (green) and dead (red) cells were
counted on the 45 images collected for control and HHC10 modified 5% HA, obtaining a
total number of cells. The number of live cells was divided by the number of total cells to
determine percent viability.

4.2.14 Osteoblast Proliferation on Modified 5% HA
NHOsts isolated from a 2 year old male were cultured to 80% confluence and
diluted to 10,000 cell per mL of OBM. Then 1 mL of the NHOst solution was added to
nine wells containing autoclaved 5% HA discs. NHOst proliferation was evaluated using
the alamarBlue® assay from Life Technologies.14,60-63 The absorbance of the alamarBlue
reagent in the OBM was collected for all nine samples at each time point. The absorbance
of the OBM from the HHC10 modified 5% HA was normalized to the control unmodified
5% HA.

4.2.15 Statistics
A one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used
to determine the averages and statistical differences between the HHC10 immobilization
and amount released, the E. coli NPN uptake factor and OD600 nm for linked and free
HHC10, and the NHOst attachment, viability and proliferation all at the p<0.05 level of
significance and all data is reported as mean ± standard error.
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4.3 Results
4.3.1 Covalent Antimicrobial Peptide Immobilization
To add antimicrobial activity to the 5% HA composite HHC10 was covalently
immobilized to the surface. The covalent linkage of HHC10 to the 5% HA controls the
location of the antimicrobial, resulting in a localized treatment aimed at preventing
bacterial colonization and possible biofilm formation. The 5% HA composite was the only
composite evaluated due to its mechanical similarity to non-loading bearing bone (Chapter
2) and the consistent, increased osteoblast attachment and proliferation on all days
examined (Chapter 3).
To immobilize HHC10 to the surface of the 5% HA discs, warm (60°C) samples
were immersed in a 1 mM solution of 16-ene (THF) for 1 hour at room temperature.
Samples were removed from solution and placed onto a 0.1 torr vacuum line for 24 hours.
The modified samples were analyzed using diffuse reflectance infrared Fourier transform
(DRIFT) spectroscopy. The peaks corresponding to the asymmetric and symmetric
methylene stretches, at 2921 and 2852 cm-1, confirm the presence of the 16-ene on the
surface (Figure 4.5).36,56,59 The peak positions are indicative of an organic acid film that
contains gauche and trans interactions. The presence of both types of interactions is a result
of the surface topography of the 5% HA material, observed using SEM.
The acid head group binding mode and tail group functionality was determined by
looking at the carboxylic acid region of the DRIFT spectrum (Figure 4.5). The solid 16ene spectrum contains peaks at 1709, 1434 and 1295 cm-1 corresponding to the νC=O, vC-O
and vC-O-H of the free carboxylic acid and the peak attributed to the vC=C at 1642 cm-1. The
spectrum of the modified substrate contains a broad peak centered at 1540 cm-1 that is the
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result of the carboxylate stretch, which indicates a bidentate organic acid binding mode.
Most importantly, the immobilized acid spectrum also contains a peak at 1651 cm-1 which
is attributed to the alkene (vC=C), free at the film interface that may be used for subsequent
organic reactions.
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Figure 4.5: DRIFT spectra indicating successful surface modification of 5% HA with 16heptadecenoic acid. A) Methylene stretching region, νCH2 asymm= 2921 cm-1 and νCH2 symm=
2852 cm-1 indicating the presence of the acid film after solvent rinse. B) Acid head group
binding region with peaks indicative of a bidentate binding mode for the attached acid (red
spectra) at 1558, 1538 and 1521 cm-1 and the free interfacial νC=C at 1651 cm-1.

The immobilization of HHC10 was achieved using a one-step alkene-thiol click
reaction, where a sacrificial cysteine residue (thiol side chain) appended to the AMP reacts
with the terminal alkene of the formed film. 16-ene modified 5% HA discs were placed in
a 1 mg/mL HHC10 solution containing 0.5 mg/mL Irgacure 2959 in 10:1 ddH2O:DMF.51
The HHC10 solution, containing the 16-ene modified 5% HA discs, was reacted under 365
nm UV light for 3 hours with N2 purge. The successful linkage of HHC10 to the 16-ene
films was confirmed using DRIFT spectroscopy, by comparing lyophilized HHC10 solid
powder to HHC10 that had been linked to 5% HA discs (Figure 4.6).
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Figure 4.6: DRIFT spectra indicating successful immobilization of HHC10. A) Thiol
stretching before (blue) and after (red) peptide linking, showing the loss of the S-H stretch.
B) Sulfide bond stretches before (blue) and after (red) peptide immobilization
corresponding to νC-S cysteine, solid at 702 cm-1 and νC-S cysteine and νC-S acid to peptide at 735, 716,
673 and 652 cm-1. C) Amide I (νC=O) and amide II (νN-H) bands for solid (blue) and linked
peptide (red) indicating the presence on the peptide on the 5% HA composite.
The solid HHC10 contained peaks corresponding to the vS-H at 2661 cm-1, vC-S at
702 cm-1 and vamide I and vamide II at 1661 and 1640 cm-1. In the linked HHC10 spectra, the
vS-H peak is no longer present and the single vC-S stretch has split into two sets of peaks that
are shifted to 735, 716, 673 and 652 cm-1. These changes are indicative of successful
immobilization of HHC10 because the click reaction takes place between the cysteine’s
side chain thiol and forms a new sulfide bond. The amide I and II region of the DRIFT
spectrum was also examined. In the linked HHC10 the vamide I was observed at 1660 cm-1
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and the vamide II at 1640 cm-1, matching those observed in the solid HHC10. The changes
observed in the thiol and sulfide regions, coupled with the persistence of the amide I and
II, confirm the successful immobilization of HHC10 to the 5% HA composite.

4.3.2 Quantification of Antimicrobial Peptide Immobilization
on 5% HA
The amount of HHC10 that was covalently linked to the 5% HA composites was
determined using fluorescence. HHC10 modified 5% HA discs were prepared using the
alkene-thiol linker system described in Section 4.2.3. Ten discs were covalently modified
and the fluorescence of the reaction solution at 342 nm, due to the four tryptophan residues
within HHC10, was correlated to the amount of HHC10 that had been linked.
By monitoring the fluorescence emission and using the calibration curve (Figure
4.7), the average amount of AMP immobilized using this alkene-thiol linker system was
found to be 470 ± 20 μg HHC10 per 5% HA disc. The 5% HA discs used here weigh on
average 0.053 grams, which translates to an antimicrobial loading of 8850 ± 90 μg HHC10

Fluorescence Intensity

per gram of modified 5% HA composite.
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Figure 4.7: Calibration curve used for the quantification of the amount of immobilized
HHC10 on the 5% HA composites.
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4.3.3 Quantification of Antimicrobial Peptide Released from
HHC10 Modified 5% HA
The quantity remaining and stability of immobilized HHC10 over time in aqueous
solution was evaluated using Direct Infusion Q-TOF MS. HHC10 modified 5% HA discs
were soaked in ddH2O for 1, 3.5 and 24 hours. At each time point the discs were removed
and the ddH2O was analyzed. The limit of detection of HHC10 in ddH2O using this method

Mass Spec Counts

was found to be 9.9x10-9 M and the limit of quantification was 3.0x10-8 M (Figure 4.8).
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Figure 4.8: Calibration curve used to quantify the amount of HHC10 released into solution.
After 1 hour the concentration of HHC10 in the ddH2O was 3.71x10-7 ± 0.73x10-7
M, after 3.5 hours the total concentration of HHC10 in solution was 5.01x10-7 ± 0.50x10-7
M and following 24 hours of soaking the total concentration of HHC10 in solution was
5.67x10-7 ± 0.20x10-7 M. Using the determined concentrations and the sample volume, the
corresponding mass of HHC10 in solution was determined. After 1 hour the average mass
of HHC10 released from the modified 5% HA discs was 1.15 ± 0.23 μg, then after 3.5
hours the total amount of HHC10 released was 1.55 ± 0.15 μg and after soaking for 24
hours the total mass of HHC10 released from the composite and into the ddH2O was 1.75
± 0.06 μg. The amount of HHC10 liberated from the modified 5% HA significantly
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increased between 1 and 3.5 hours, but the increase was not significant between 3.5 and 24
hours. The average percentage of HHC10 that remained linked to the 5% HA was
quantified using the average loading determined in Section 4.3.2. After 24 hours of soaking
the modified 5% HA discs, the average amount of HHC10 that remained immobilized
using the developed alkene-thiol linker system was 99.63 ± 0.01% (Figure 4.9).
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Figure 4.9: The percentage of Inverso-CysHHC10 that remains linked to 5% HA using
the alkene-thiol linker system through a 24 hour soak in ddH2O, shown as mean ± standard
error, p<0.05.

4.3.4 Escherichia coli NPN Uptake Factor on Modified 5% HA
A proposed mechanism of AMP action is through cell membrane disruption, where
the AMPs form trans-membrane pores that result in the collapse of the cell membrane and
leads to cell death.43,44,47 Changes in E. coli membrane permeability were evaluated using
the NPN uptake assay. E. coli cultures were grown to 0.5 OD600 nm and treated with HHC10
modified 5% HA discs. The fluorescence intensity of the samples was collected and the
NPN uptake factors were determined and normalized to untreated E. coli. The normalized
NPN uptake factors were: control untreated E. coli: 1.00 ± 0.01 and HHC10 modified 5%
HA treated E. coli: 1.35 ± 0.02 (Figure 4.10). The normalized NPN uptake factor of the
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treated E. coli was statistically higher than the NPN uptake factor of untreated E. coli,
indicative of increased membrane permeability. Which clearly demonstrates that the
HHC10 retains its activity against E. coli when it is covalently immobilized to a 5% HA

Normalized NPN Uptake Factor

composite using the developed alkene-thiol linker system.
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Untreated E. Coli
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Figure 4.10: Normalized NPN uptake factor for untreated E. coli and E. coli treated with
HHC10 modified 5% HA discs. Data shown as mean ± standard error, p<0.05. E. coli
treated with modified discs exhibit increased membrane permeability.

4.3.5 Escherichia coli Bacterial Turbidity Tests with Modified
5% HA
The activity of linked HHC10 was further evaluated by monitoring the growth of
E. coli in planktonic culture when incubated with HHC10 modified 5% HA. After
incubating a 0.1 OD600 nm E. coli solution for 2.5 hours with modified 5% HA, the OD600
nm

was measured for all samples and normalized to untreated E. coli. The normalized

average OD600 nm for E. coli solutions were: control untreated E. coli: 1.00 ± 0.02 and
HHC10 modified 5% HA treated E. coli: 0.24 ± 0.01 (Figure 4.11). Based on the decreased
OD600

nm,

the growth of E. coli incubated with HHC10 modified 5% HA discs was
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effectively inhibited. Further demonstrating the immobilized HHC10 retains its activity
against the E. coli.
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Figure 4.11: Normalized OD600 nm for untreated E. coli and E. coli treated with HHC10
modified 5% HA discs. Data shown as mean ± standard error, p<0.05. E. coli treated with
modified discs exhibit decreased OD600 nm and decreased bacterial growth in culture.

4.3.6 Inverso-CysHHC10 Antimicrobial Activity in Solution
and Linked to Modified 5% HA
Based on the NPN uptake assay and bacterial turbidity test, it was clearly shown
that the immobilized HHC10 retains its antimicrobial activity against E. coli. The efficacy
of the linked AMP was further compared to the free, in solution HHC10 to determine the
concentration dosage that the linked AMP was equally as effective as.
E. coli was cultured and treated as described in Section 4.2.8. Using the NPN uptake
assay, the fluorescence intensity of the samples was collected and the NPN uptake factors
were determined and normalized to the untreated E. coli. The NPN uptake factors were:
control untreated E. coli: 1.00 ± 0.01; 10 μM HHC10 treated E. coli: 1.36 ± 0.01 and
HHC10 modified 5% HA treated E. coli: 1.35 ± 0.02. (Figure 4.12). The NPN uptake
factors of the treated E. coli, both 10 μM HHC10 and HHC10 modified 5% HA discs, were
statistically higher than that of untreated E. coli. Further, the NPN uptake factor of linked
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and 10 μM HHC10 were statistically equivalent, demonstrating that immobilized HHC10

Normalized NPN Uptake Factor

is as effective as a 10 μM AMP solution.
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Figure 4.12: NPN uptake assay for E. coli treated with 10 μM and linked HHC10, shown
as mean ± standard error, p<0.05. Both treated E. coli solutions have a statistically higher
NPN uptake factor than untreated E. coli and are statistically equivalent.

E. coli was cultured and treated as described in Section 4.2.9. Using the bacterial
turbidity test, the OD600

nm

of E. coli solutions were collected and normalized to the

untreated bacteria solutions. The normalized OD600 nm for the E. coli solutions were: control
untreated E. coli: 1.00 ± 0.02; 10 μM HHC10 treated E. coli: 0.25 ± 0.02 and HHC10
modified 5% HA treated E. coli: 0.24 ± 0.01 (Figure 4.13). The OD600 nm of the E. coli
incubated with both the 10 μM HHC10 and HHC10 modified 5% HA discs were
statistically lower than the untreated E. coli. Additionally, the OD600 nm of E. coli treated
with 10 μM HHC10 and linked HHC10 were statistically equal, confirming the linked
HHC10 prevents E. coli growth as effectively as a 10 μM HHC10 solution.
Based on both the NPN uptake assay and E. coli bacterial turbidity test, the linked
HHC10 is equally effective against E. coli as a 10 μM HHC10 solution.
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Figure 4.13: Bacterial turbidity tests for E. coli treated with 10 μM and linked HHC10,
shown as mean ± standard error, p<0.05. Both treated E. coli solutions have a statistically
lower OD600 nm than untreated E. coli and are statistically equivalent.

4.3.7 Osteoblast Attachment to Modified 5% HA
To evaluate if the immobilization of HHC10 affected the increased osteoblast
attachment observed on the unmodified 5% HA, NHOsts were cultured and seeded onto
sterilized, HHC10 modified 5% HA discs. Nine discs were placed into a 48 well plate per
time point and loaded with 10,000 NHOsts. After 1, 4 and 7 days the cells were imaged
using the Live/Dead® Viability/Cytotoxicity assay kit. Five images per disc were collected
(Figure 4.14) and the number of live cells was counted and normalized to the control.
Day 1

Day 4

Day 7

Unmodified
5% HA

HHC10
modified
5% HA

Figure 4.14: Representative Live/Dead® fluorescent images of osteoblasts attached to
control unmodified and HHC10 modified 5%HA composites on Days 1, 4 and 7.
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On Day 1 the normalized average number of live osteoblasts per view was: control
unmodified 5% HA: 100.0 ± 7.7 and HHC10 modified 5% HA: 105.5 ± 8.7 (Figure 4.15).
The HHC10 modified 5% HA composites had statistically the same number of attached
live cells as unmodified 5% HA on Day 1.
On Day 4 the normalized average number of live osteoblast cells per view was:
control unmodified 5% HA: 100.0 ± 9.4 and HHC10 modified 5% HA: 101.1 ± 9.2 (Figure
4.15). Again, the HHC10 modified 5% HA discs had the statistically same number of cells
per view as unmodified 5% HA.
The normalized average number of live osteoblast cells per view on Day 7 was:
control unmodified 5% HA: 100.0 ± 6.1 and HHC10 modified 5% HA: 103.9 ± 4.8 (Figure
4.15). The amount of attached live cells was once again statistically the same for HHC10

Normalized Average Live Cells/View

modified and unmodified 5% HA.
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Figure 4.15: Days 1, 4 and 7 normalized average number of live osteoblasts attached to
control unmodified and HHC10 modified 5% HA composites. Data represented as mean ±
standard error, p<0.05. The average number of attached live cells is statistically equal on
all days examined.

The number of live osteoblasts attached the HHC10 modified 5% HA was
statistically equal to the number attached to unmodified 5% HA on all days examined.
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These results prove that the covalent immobilization of the AMP does not have a negative
effect on the osteoblasts cultured on the composites.

4.3.8 Osteoblast Viability on Modified 5% HA
To examine the effect of immobilizing HHC10 on osteoblast viability, NHOsts
were cultured and seeded onto sterilized, HHC10 modified 5% HA discs. Nine sterilized
discs per time point were placed into a 48 well plate and loaded with 10,000 NHOsts. After
1, 4 and 7 days the cells were imaged using the Live/Dead® Viability/Cytotoxicity assay
kit. Five images per disc were collected. The number of live cells was divided by the total
number of cells to determine the percent viability of the NHOsts.
On Day 1 the percent cell viability was: control unmodified 5% HA: 84.4 ± 1.8 and
HHC10 modified 5% HA: 85.6 ± 1.7 (Figure 4.16). The HHC10 modified and unmodified
5% HA had same percentage of attached viable cells.
The percent cell viability on Day 4 was: control unmodified 5% HA: 74.4 ± 2.5 and
HHC10 modified 5% HA: 78.6 ± 3.0 (Figure 4.16). Again both modified and unmodified
5% HA had statistically the same percent cell viability.
On Day 7 the percent cell viability was: control unmodified 5% HA: 81.6 ± 1.2 and
HHC10 modified 5% HA: 87.1 ± 1.3 (Figure 4.16). The percentage of viable cells on the
HHC10 modified 5% HA was statistically higher than that of cells on unmodified 5% HA.
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80
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Figure 4.16: Days 1, 4 and 7 percent viability of attached cells on control unmodified and
HHC10 modified 5% HA composites. * = statistically higher than control for that day. Data
represented as mean ± standard error, p<0.05. The percent viability is equal on Day 1 and
4 and statistically higher on Day 7.

The immobilization of HHC10 also does not adversely affect the percent viability
of the attached osteoblasts. At the longest time point the percent viability was greater on
the HHC10 modified 5% HA.

4.3.9 Osteoblast Proliferation on Modified 5% HA
To determine if the presence of HHC10 had an effect on osteoblast proliferation,
NHOsts were cultured and seeded onto sterilized, HHC10 modified 5% HA discs. Nine
discs at each time point were placed into 48 well plates and loaded with 10,000 cells. Before
evaluating proliferation, the alamarBlue® reagent was diluted into the OBM. After 1, 4
and 7 days the OBM was examined using UV-VIS spectroscopy. The absorbance of the
OBM from each well was collected and normalized to control unmodified 5% HA.
On Day 1 the normalized average absorbance was: control unmodified 5% HA:
100.0 ± 2.5 and HHC10 modified 5% HA: 103.2 ± 4.2 (Figure 4.17). The amount of cell
proliferation supported was statistically equal between modified and unmodified 5% HA.
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The normalized average absorbance on Day 4 was: control unmodified 5% HA:
100.0 ± 1.8 and HHC10 modified 5% HA: 98.1 ± 2.8 (Figure 4.17). Again, cell
proliferation was equally supported on both the control and HHC10 modified 5% HA discs.
By Day 7 the normalized average absorbance was: control unmodified 5% HA:
100.0 ± 4.6 and HHC10 modified 5% HA: 101.2 ± 4.3 (Figure 4.17). Similar to the previous

Normalized Absorance @ 570 nm

days, the absorbance was statistically equal between control and modified samples.
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Figure 4.17: Days 1, 4 and 7 normalized absorbance of OBM for control unmodified and
HHC10 modified 5% HA composites. Data represented as mean ± standard error, p<0.05.
The amount of cell proliferation is statistically equal on all days examined.

The HHC10 modified 5% HA discs supported cell proliferation equally as well as
the unmodified 5% HA on all days examined. Again, these results demonstrate that the
immobilization of HHC10 does not affect the increased cell proliferation observed on the
5% HA composite.

4.4 Discussion
Implant associated infections are difficult to eliminate because of their antibiotic
resistant characteristics.15,19-21 Frequently, by the time the infection is discovered it is in an
advanced stage, when the removal of the implant is the best approach for treatment. 2,13-
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15,17,27

To avoid this colonization, an antimicrobial molecule that is localized to the graft

and is present upon implantation is desirable.31-33,36,37 To also avoid the growing concern
over antibiotic resistance, an immobilized antimicrobial peptide was investigated.41-44 The
AMP was covalently attached to the composite 5% HA materials through a two-step
alkene-thiol click reaction. DRIFT spectroscopy confirmed both of the steps of the
modification proceeded successfully and Q-TOF MS confirmed the quantity and stability
of the attached HHC10. HHC10 modified 5% HA discs were then sterilized by autoclaving
and evaluated biologically.
Antibacterial efficacy, of both the linked and in solution HHC10, was evaluated
through the NPN uptake assay and bacterial turbidity tests.36,54-56 A proposed mechanism
of AMP action is through cell membrane disruption, where the AMPs form transmembrane pores that results in the collapse of the cell membrane and cell death.41,44
Changes in membrane permeability for E. coli treated with HHC10 modified 5% HA and
10 μM HHC10 were evaluated using the NPN uptake assay. NPN uptake was increased by
40% for the E. coli treated using both types of HHC10. Further, the uptake was statistically
equal for both the linked HHC10 and the 10 μM HHC10 (p<0.05), demonstrating that the
linked AMP permeabilizes the E. coli membrane as well as a 10 μM solution. The LC99.9
of “free” HHC10 is 8 μM and the effective dosage of the linked HHC10 is 10 μM, showing
that the linked HHC10 retains its activity against E. coli through linkage.49
The prevention of bacterial growth in culture was monitored using the bacterial
turbidity test.36,56 As bacteria are grown in culture, they create a turbid solution, where the
greater the concentration of bacteria, the greater the turbidity of that solution. Through this
assay a similar HHC10 effectiveness was observed to seen in the NPN uptake assay. Both
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the HHC10 modified 5% HA discs and with 10 μM HHC10 resulted in a 75% decrease in
E. coli solution turbidity. This decrease was equal for both HHC10 treated E. coli samples.
This assay confirmed that the linked AMP is equally as effective at preventing the growth
of E. coli in culture as the 10 μM HHC10 solution. The bacterial turbidity test coupled
with the NPN uptake assay verified that the covalent immobilization of HHC10 does not
render the AMP inactive, but rather the activity is only slightly diminished.
Since the goal was to develop a material that increased osteoblast performance and
simultaneously decreased bacterial attachment, once the HHC10 had been immobilized to
the 5% HA the material and evaluated for its antibacterial properties, osteoblast
performance on the HHC10 modified 5% HA materials was re-examined. The presence of
HA at the composite interface was shown to increase osteoblast response on unmodified
5% HA discs. When the osteoblast attachment, viability and proliferation were examined
on HHC10 modified 5% HA, it was shown that the immobilization of HHC10 does not
affect the bone cell performance. On Day 1 and Day 4, the number of attached cells, percent
cell viability and cell proliferation were all comparable on HHC10 modified and
unmodified 5% HA. On Day 7 the number of attached cells and cell proliferation were
statistically the same and the percent cell viability was increased on HHC10 modified 5%
HA over control.
These osteoblast performance assays consistently demonstrated that the HHC10
modification did not impede with the osteoblast response. This indicates that despite the
immobilization of HHC10 onto the 5% HA composites, there is still sufficient surface
contact area available for cells to interact. If the HHC10 formed a complete layer on the
CaAlO:HA surface the cells would not be able to interact with the composite and the
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cellular response would decrease. Previous work had demonstrated that “free” HHC10
induced hemolysis in only 1% of erythrocytes.49 Although the work here did not explicitly
quantify the amount of cell death, it was clearly shown that HHC10 immobilization did not
decrease the number of attached live cells or the percent viability of those cells.
Based on the biological evaluation of the HHC10 modified 5% HA composite, the
multifunctional material had been developed. The 5% HA had an elastic modulus and
modulus of rupture that was similar to non-load bearing cancellous bone and consistently
resulted in increased osteoblast attachment, viability and proliferation. Chemical
functionalization with an antimicrobial peptide added antibacterial properties to the
material and did not sacrifice the bone cell performance. Based on the mechanical and
biological evaluation performed on the HHC10 modified 5% HA it was determined that
this composite is suitable for a synthetic bone graft and has the ability to address multiple
physiological stresses that would be placed on it.

4.5 Conclusions
DRIFT analysis confirmed the RT-formed 5% HA composite was successfully
functionalized with the potent antimicrobial peptide Inverso-CysHHC10. Immobilization
was achieved using the highly efficient alkene-thiol click reaction and the HHC10
remained localized on the 5% HA disc for at least 24 hours. Through covalent
immobilization the HHC10 retained its bactericidal activity and functioned with the
potency of a 10 μM HHC10 solution, based on the increased E. coli membrane permeability
and the reduced growth of E. coli in culture. Most importantly, the linked HHC10 did not
adversely affect the increased osteoblast response observed on the unmodified 5% HA
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composites. Cell attachment and proliferation on HHC10 modified and unmodified 5% HA
was statistically equivalent on all the days examined and percent cell viability was
increased on the longest time point. These results clearly demonstrate that the increased
osteoblast response is not affected by the attachment of the antimicrobially active HHC10.
Further the alkene-thiol linker system utilized here can be extended to other system where
the material contains reactive surface hydroxyl groups and the antimicrobial molecule
contains or can be amended to include a sacrificial thiol functionality.
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Chapter 5: Conclusions
5.1 Effect of Hydroxyapatite Incorporation into Calcium
Aluminum Oxide
To improve the biocompatibility and osteogenic ability of the CaAlO material, it
was cast as part of a composite with the osteoinductive and osteoconductive calcium
phosphate material, HA.1-3 HA was utilized due to its chemical similarity to the mineral
component of natural bone and its previously demonstrated ability to increase in vivo bone
regeneration.2,4-6 By pairing small amounts of the osteogenic HA with the mechanically
strong CaAlO, a new potential bone scaffold material was developed and evaluated.

5.1.1 Phase Composition of Cast Composites
The composites were formed using a room temperature cast where three different
aggregate sizes of CaAlO were mixed with ground Ca3(PO4)2 and hydrated using a dilute
H3PO4 solution. Composites containing 1-5, 10, 15, 20 and 25% HA were successfully
formed and evaluated for their phase composition. When CaAlO was exclusively cast,
three different calcium aluminum phases were found using PXRD, CaAl4O7, CaAl2O4 and
Ca3Al2(OH)12, and when Ca3(PO4)2 was cast two difference phases were detected
Ca5(PO4)3OH (HA) and CaHPO4·2H2O. When CaAlO and Ca3(PO4)2 were cast together
the same five phases were observed, indicating that there are no cross reactions taking place
and there is no mixing of the two primary materials (CaAlO and Ca3(PO4)2). SEM-EDS
further confirmed the presence, abundance and distribution of the cast HA at the composite
interface where in vitro cellular interactions can occur.
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5.1.2 Mechanical Properties of Cast Composites
Two different post hydration processes were examined to determine the effect on
the mechanical properties of the cast composites. The post hydration methods tested were
1) drying at room temperature and 2) sintering at 1000°C for 4 hours. These methods were
evaluated because CaAlO derives its strength from hydration with water at room
temperature, whereas HA derives its strength from sintering. The materials were evaluated
for both the effect of increasing amount of HA in the composite and the effect of post
hydration processing. The addition of HA to the composite was shown to significantly
decrease the mechanical strength with larger amounts of HA (>10%), to the point where
these composites were not similar in strength to natural non-load bearing cancellous bone.
Post hydration processing also played a significant role in composite strength. All sintered
composites had statistically lower elastic moduli and >10% HA composites had lower
moduli of rupture. Ultimately the low percentage HA composites were the closest match
to structural cancellous bone and were evaluated for ability to increase osteoblast response.

Table 5.1: Mechanical properties of natural bone and the 5% HA developed in this work.
Elastic Modulus (GPa)

Modulus of Rupture (MPa)

Load Bearing
Cortical Bone

15-22

60-75

Non-Load Bearing
Cancellous Bone

3-11

4-9

RT-formed 5% HA
Composite

8.8-11

5.7-7.1
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5.1.3 Osteoblast Response on 1-5% HA
The low percentage of HA composites that were mechanically similar to non-load
bearing cancellous bone were examined for increased osteoblast response. Osteoblast cells
were cultured and seeded onto sterilized 1-5% HA discs and evaluated for cellular
attachment, percent viability and proliferation on Days 1, 4 and 7 after seeding.
Significantly increased osteoblast attachment was observed on all 1-5% HA composites on
Days 4 and 7. However, on Day 1 only the 5% HA had significantly increased osteoblast
attachment. Cell viability was significantly increased on all composites on Days 4 and 7,
and on 1%, 4% and 5% HA on Day 1. Cell proliferation was increased on Days 4 and 7 for
all composites and on 4% and 5% HA on Day 1. The 5% HA had osteoblast attachment
and proliferation that was significantly higher than all other composites on the days
examined. Therefore the 5% HA is the composite that is mechanically the most similar to
non-load bearing cancellous bone and also increases osteoblast response the most over all
other composites.

5.2 Inverso-CysHHC10

Antimicrobial

Activity:

Surface

Immobilized vs. in Solution
After determining that the 5% HA composite was the most suitable material
mechanically and for increased osteoblast response, the composite was functionalized to
prevent E. coli growth.7-9 The broad spectrum antimicrobial peptide HHC10 was covalently
linked to the 5% HA in a two-step alkene-thiol click reaction, where the material serves as
the delivery vehicle for the antimicrobial, and the 16-ene film serves as the organic spacer
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group giving the AMP steric freedom at the interface.10,11 Mass spectral analysis revealed
the stability of the newly formed sulfide bond that kept greater than 99.6% of the HHC10
localized to the material through 24 hours soaking in water. The activity of the linked
HHC10 was determined through the NPN uptake factor and bacterial turbidity test.
Increased bacteria cell membrane permeability was evaluated using the NPN uptake
assay.12,13 Results indicated increased NPN uptake for E. coli treated with HHC10 modified
5% HA versus unmodified 5% HA, as a result of AMP activity and membrane pore
formation. The growth of E. coli in planktonic culture was also significantly reduced as
indicated by the OD600 nm in the bacterial turbidity test.14,15 The amount of AMP covalently
linked to the 5% HA composite was as effective against E. coli as a 10 μM HHC10 solution,
which is slightly greater than the 8 μM LC99.9 of free Inverso-CysHHC10.10,11 Both of
these assays confirm that HHC10 retains its antimicrobial activity through the alkene-thiol
immobilization, resulting in the antimicrobially active 5% HA interface.

5.3 Osteoblast Response on Inverso-CysHHC10 Modified
5% HA
In an ideal multifunctional system, the function of one modification should not be
affected by the other. Therefore, once the covalent attachment and antimicrobial evaluation
of HHC10 was completed, the increased osteoblast response observed on unmodified 5%
HA was re-examined. Osteoblasts were cultured and seeded onto sterilized HHC10
modified 5% HA and examined for their attachment, viability and proliferation on Days 1,
4 and 7. Statistically equivalent cellular attachment was observed on HHC10 modified and
unmodified 5% HA on all days examined. The extent of osteoblast proliferation on the
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HHC10 modified 5% HA was again statistically equal to the unmodified 5% HA on Days
1, 4 and 7. Finally percent cell viability was the same on HHC10 modified and unmodified
5% HA on Days 1 and 4, and was statistically higher on modified 5% HA on Day 7. These
outcomes demonstrate that the independent functions of the 5% HA composite are not
compromised when the AMP is immobilized to the material surface.

5.4 Impact and Future Work
Through the execution of this project, the CaAlO material was physically and
chemically improved for applicability as a bone scaffold material. The incorporation of the
osteogenic HA into the material resulted in increased osteoblast response without the
implementation of chemical modification. The use of an alkene-thiol click reaction to link
an antimicrobial peptide to the composite also demonstrates an improved method for the
addition of antibacterial activity to these bone scaffold materials.11,16
Literature has shown that through the chemical immobilization of cell adhesion
peptides and osteoinductive proteins osteoblast performance can be significantly increased
on a variety of materials.14,17-20 However, the enhanced osteoblast response observed on
the unmodified CaAlO based composites that remain mechanically similar to non-load
bearing bone is the first result of this nature. By increasing bone cell response through this
materials-based approach the extent of functionalization and introduction of chemicals to
the materials has been significantly reduced.
The covalent immobilization of Inverso-CysHHC10 to the 5% HA composite that
remains active through sterilization is a significant contribution towards the limitation of
implant associated infections. The significance of the antimicrobial peptide being localized
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to the material is that it allows for effective broad spectrum antimicrobial activity that is
persistent at the location of implantation. Most importantly, by using an AMP instead of
an antibiotic, this modification approach plays a critical role in limiting the development
of antibacterial resistance among strains of bacteria in vitro and in vivo.21-24
The design of a multifunctional composite material that actively enhances
osteoblast response and decreases bacterial growth is significant because it represents an
advancement in the development of biomaterials that are able to address multiple
physiological strains that may be placed on the material in an in vivo setting. Further, in an
ideal multifunctional material one function would not be effected by the other, and the
system developed here demonstrates that these biological functions work in synergy on the
material. The modified composites designed here cooperatively address the problems
associated with mechanical and biological bone graft failure.
The reaction sequence used to modify the 5% HA interface is further applicable to
other relevant biomaterial surfaces. Any interface that contains the reactive surface
hydroxyl and μ-oxo groups can be functionalized with using this alkene-thiol approach.
Many current metal oxides used in total joint replacements and arterial and venous stents
contain these groups and their functionality could be improved through antimicrobial
modification using an alkene-thiol click linker system.
In the future, methods to create macroporosity in the materials without
compromising mechanical strength would be desirable. A potential approach is to integrate
the fibrous protein collagen into the material, as natural bone is approximately 60%
hydroxyapatite and 40% collagen by dry mass. Also, composites that are between 5-10%
HA may be examined mechanically and biologically because the trend observed in this
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work is that as the HA percentage increases the osteoblast response increases, but the
mechanical strength decreases. The alkene-thiol linker system could be utilized to link a
natural AMP. The HHC10 used here is effective in vitro, however it is a synthetic AMP.
The human immune system is composed of a large variety of natural AMP’s including
defensins, cathelicidins and histatins that may be more attractive options in human
biomaterial applications.25-28
Ultimately, in vivo studies using a critical sized bone defect are necessary to
evaluate the ability of the unmodified and HHC10 modified 5% HA to increase new bone
formation in a physiological setting.6 Further in vitro bacterial testing with additional
biofilm forming bacteria including S. aureus and S. epidermidis would be beneficial to
demonstrate that the linked AMP retains its broad spectrum antibacterial activity.21,29-31
Upon completing these additional in vitro studies, an in vivo implant associated infection
model would be necessary to fully evaluate the material for its applicability as a synthetic
bone scaffold.
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